[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 950
1. Kauh J, Koshy M, Gunthel C, Joyner MM, Landry J, Thomas CR Jr: Management of anal cancer in the HIV-positive population. Oncology (Williston Park); 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in the HIV-positive population.
  • Squamous cell anal cancer remains an uncommon entity; however, the incidence appears to be increasing in at-risk populations, especially those infected with human papillomavirus (HPV) and human immunodeficiency virus (HIV).
  • Given the ability to cure this cancer using synchronous chemoradiotherapy, management practices of this disease are critical.
  • This article considers treatment strategies for HIV-positive patients with anal cancer, including the impact on chemoradiation-induced toxicities and the role of highly active antiretroviral therapy in the treatment of this patient population.
  • Additional changes to the chemotherapy dosing, such as giving 5-FU continuously and decreasing mitomycin dose, are evaluated and considered in relation to radiation field sizes in an effort to reduce toxicity, maintain local tumor control, and limit need for colostomy.
  • The impact of the immune system in patients with HIV and squamous cell carcinoma of the anus and the associated response to therapy remains unknown.
  • Continued studies and phase III trials will be needed to test new treatment strategies in HIV-infected patients with squamous cell cancer of the anus to determine which treatment protocols provide the greatest benefits.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / epidemiology. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. HIV Infections / epidemiology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / methods. Combined Modality Therapy / methods. Comorbidity. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome


2. Brewster DH, Bhatti LA: Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002. Br J Cancer; 2006 Jul 3;95(1):87-90
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002.
  • In Scotland, since 1975-1979 (world) age-standardised incidence of squamous cell carcinoma of the anus has more than doubled, reaching 0.37 per 100,000 in males and 0.55 in females during 1998-2002, being somewhat higher in socioeconomically deprived areas.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] J Natl Cancer Inst. 1984 Mar;72(3):609-15 [6583444.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Acta Chir Scand. 1989 Mar;155(3):191-7 [2741627.001]
  • [Cites] J Public Health Med. 1991 Nov;13(4):318-26 [1764290.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Feb 1;11(2):178-82 [8556400.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Ann Transplant. 1997;2(4):59-66 [9869880.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):630-1 [15870433.001]
  • [Cites] Sex Transm Infect. 2005 Oct;81(5):367-72 [16199733.001]
  • [Cites] Am J Surg. 2005 Nov;190(5):732-5 [16226949.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Sex Health. 2004;1(3):137-40 [16335300.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):414-7 [11818208.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):505-7 [12888821.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [ErratumIn] Br J Cancer. 2006 Aug 7;95(3):423
  • (PMID = 16721368.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360500
  •  go-up   go-down


3. da Costa e Silva IT, Gimenez FS, Guimarães RA, Camelo RT, Melo MN, de Barros FS, Daumas A, Cabral CR, Guimarães EL: [Anal cytology as a screening method for early detection of anal cancer: are hydrophilic cotton smears really unsatisfactory?]. Acta Cir Bras; 2005 Jan-Feb;20(1):109-14
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cytology as a screening method for early detection of anal cancer: are hydrophilic cotton smears really unsatisfactory?].
  • [Transliterated title] Citologia anal como método de rastreamento para a detecção precoce do cancer anal: esfregaços com algodão hidrófilo são mesmo insatisfatórios?
  • METHODS: 318 consecutive patients were examined at the Ambulatório Araújo Lima of Hospital Universitario Getúlio Vargas in the Anal Cancer Prevention Week and were sampled for the performance of analpap.
  • The ability of cotton in producing satisfactory anal cytologic readings as compared to dacron and cytologic brush was analised.

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15810472.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] POR
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Brazil
  •  go-up   go-down


Advertisement
4. Rubio CA, Nilsson PJ: Squamous-cell carcinoma of the anus with high intratumoral lymphocytosis and its clinical implications. Anticancer Res; 2008 Jul-Aug;28(4C):2469-72
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anus with high intratumoral lymphocytosis and its clinical implications.
  • BACKGROUND: It has been claimed that patients with squamous cell carcinoma of the anal canal (SCCAC) showing intraepithelial lymphocytes have a poor prognosis.
  • Between 5 and 15 years follow-up, all SCCAC/HTIL patients had survived, whereas during the same time interval 28 (10.4%) of the SCCAC patients without HTIL had died of their tumor.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphocytes, Tumor-Infiltrating / pathology. Lymphocytosis / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751436.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


5. Buchs NC, Allal AS, Morel P, Gervaz P: Prevention, chemoradiation and surgery for anal cancer. Expert Rev Anticancer Ther; 2009 Apr;9(4):483-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention, chemoradiation and surgery for anal cancer.
  • Management of patients with squamous cell carcinoma of the anus (SCCA) has remained virtually unchanged since the 1980s.
  • By contrast, the demographics of SCCA are evolving, with the emergence of a high-risk group of patients: HIV-positive male homosexuals are prone to develop anal intra-epithelial neoplasia and rapidly progress towards invasive SCCA.
  • By many aspects, anal cancer is similar to uterine cervix cancer - a sexually transmitted disease driven by oncogenic human papillomavirus (HPV) infection.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell
  • [MeSH-minor] Adolescent. Alphapapillomavirus / pathogenicity. Carcinoma in Situ / surgery. Carcinoma in Situ / virology. Combined Modality Therapy. Female. HIV Infections / complications. Homosexuality, Male. Humans. Male. Papillomavirus Infections / prevention & control. Papillomavirus Vaccines. Radiotherapy, Adjuvant / adverse effects. Salvage Therapy. Surgical Flaps. Surgical Wound Dehiscence / etiology. Surgical Wound Dehiscence / prevention & control. Vaccination

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - HIV InSite .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374601.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 66
  •  go-up   go-down


6. Yako-Suketomo H, Marugame T: Comparison of time trends in colon, rectum and anus cancer incidence (1973-2002) in Asia, from 'Cancer Incidence in Five Continents, Vols IV-IX'. Jpn J Clin Oncol; 2009 Mar;39(3):196-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of time trends in colon, rectum and anus cancer incidence (1973-2002) in Asia, from 'Cancer Incidence in Five Continents, Vols IV-IX'.
  • [MeSH-major] Anus Neoplasms / epidemiology. Colonic Neoplasms / epidemiology. Rectal Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233893.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Gorez E, Staumont G: [Epidermoid anal carcinoma]. Rev Prat; 2008 Oct 31;58(16):1783-92
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid anal carcinoma].
  • [Transliterated title] Carcinome epidermoïde anal.
  • Epidermoid carcinoma of the anus is a rare cancer, and conventionally affects elderly women.
  • Main predisposing factors are sexually transmitted diseases and particularly human papillomavirus (HPV) infection, variety of sexual partners, smoking, homosexuality, history of uterine cervix cancer, and immunodepression.
  • Warning signs of anal cancer are often non-specific.
  • The evaluation assessment should include lung X-ray, abdominal CT scan, and often pelvis MNR or anal endosonography.
  • Key prognostic factors are infiltration of the initial tumour and presence of lymph node metastasis.
  • First-line treament of anal epidermoid carcinoma is radiotherapy, combined with chemotherapy for extensive forms.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell
  • [MeSH-minor] Age Factors. Aged. Anal Canal / pathology. Biopsy. Combined Modality Therapy. Female. Homosexuality, Male. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19143150.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Uronis HE, Bendell JC: Anal cancer: an overview. Oncologist; 2007 May;12(5):524-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: an overview.
  • Anal cancer is a rare tumor with an incidence that has been rising over the last 25 years.
  • HIV infection is also associated with anal cancer; there is a higher incidence in HIV-positive patients but the direct relationship between HIV and anal cancer has been difficult to separate from the prevalence of HPV in this population.
  • HIV infection is also associated with anal cancer; there are increasing numbers of HIV-positive patients being diagnosed with the disease.
  • Treatment of anal cancer prior to the 1970s involved abdominoperineal resection, but the standard of care is now concurrent chemoradiation therapy, with surgery reserved for those patients with residual disease.
  • We present a case of anal cancer followed by a general discussion of both risk factors and treatment.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adenocarcinoma / therapy. HIV Infections / complications. Humans. Male. Middle Aged. Neoplasm Staging. Papillomavirus Infections / complications. Risk Factors

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17522240.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


9. Badin S, Iqbal A, Sikder M, Chang VT: Persistent pain in anal cancer survivors. J Cancer Surviv; 2008 Jun;2(2):79-83
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent pain in anal cancer survivors.
  • INTRODUCTION: Anorectal cancers are highly curable malignancies.
  • RESULTS: Two patients presented with painful anal lesions that were diagnosed as squamous cell carcinoma of the anus.
  • IMPLICATIONS FOR CANCER SURVIVORS: Treatment related lumbosacral plexopathy may be an unrecognized consequence of the successful treatment of anal carcinoma.
  • [MeSH-major] Anus Neoplasms / complications. Pain / epidemiology. Postoperative Complications / epidemiology. Survivors

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 1985 Jan;35(1):1-7 [2981416.001]
  • [Cites] CA Cancer J Clin. 2003 May-Jun;53(3):172-96 [12809410.001]
  • [Cites] Mayo Clin Proc. 1997 Sep;72 (9):823-9 [9294528.001]
  • [Cites] Clin Radiol. 2006 Dec;61(12 ):987-95 [17097418.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3283-90 [10506631.001]
  • [Cites] Am Fam Physician. 2005 Feb 15;71(4):699-706 [15742907.001]
  • [Cites] Arch Neurol. 2003 Nov;60(11):1524-34 [14623723.001]
  • [Cites] Neurology. 1985 Jan;35(1):8-15 [2981417.001]
  • [Cites] Electromyogr Clin Neurophysiol. 1990 Aug-Sep;30(5):277-82 [2226271.001]
  • [Cites] Radiother Oncol. 1996 Feb;38(2):121-30 [8966224.001]
  • [Cites] Clin J Pain. 2002 Mar-Apr;18(2):75-6 [11882769.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2006 Jun;18(5):427-8 [16817337.001]
  • [Cites] Semin Neurol. 2004 Dec;24(4):385-93 [15637650.001]
  • [Cites] Neurol Clin. 1989 May;7(2):333-60 [2657380.001]
  • [Cites] Radiother Oncol. 2001 Mar;58(3):279-86 [11230889.001]
  • [Cites] J Pain Symptom Manage. 2002 Dec;24(6):578-85 [12551807.001]
  • (PMID = 18648976.001).
  • [ISSN] 1932-2267
  • [Journal-full-title] Journal of cancer survivorship : research and practice
  • [ISO-abbreviation] J Cancer Surviv
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Lukan N, Ströbel P, Willer A, Kripp M, Dinter D, Mai S, Hochhaus A, Hofheinz RD: Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology; 2009;77(5):293-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.
  • BACKGROUND: No standard chemotherapy regimen can be defined for patients with metastatic squamous cell carcinoma of the anus due to the low incidence of this disease and the high cure rate of localized tumors.
  • Anal cancers universally express the epidermal growth factor receptor (EGFR) and KRAS mutations have not been reported in anal cancer thus far.
  • METHODS: We report on 7 patients with metastatic anal cancer treated with cetuximab - a chimeric antibody against EGFR - on a compassionate use basis along with the results of KRAS mutational analysis.
  • RESULTS: Marked tumor shrinkage was noted in several patients using cetuximab monotherapy or cetuximab/irinotecan combination as first or subsequent treatment line (usually after failure of cisplatin-based regimens).
  • Both patients had progressive disease receiving cetuximab, while the remaining 5 patients had either a partial remission (n = 3), a minor remission (n = 1) or no change lasting > or =6 months after previous rapid tumor progression.
  • CONCLUSION: Cetuximab-based treatment appears to be a valuable treatment option for patients with metastatic KRAS wild-type anal cancer after failure of or as an alternative to cisplatin/5-fluorouracil-based therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Mutation. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / antagonists & inhibitors. ras Proteins / genetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19923868.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab
  •  go-up   go-down


11. Edelman S, Johnstone PA: Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys; 2006 Sep 1;66(1):206-11
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.
  • PURPOSE: We report toxicity and survival data of human immunodeficiency virus (HIV)-infected men with anal carcinoma treated with combined modality therapy (CMT) of radiotherapy and concurrent chemotherapy.
  • METHODS AND MATERIALS: A retrospective review was performed on the records of 17 HIV-positive patients with anal squamous cell carcinoma treated with CMT at our institution between 1991 and 2004.
  • Chemotherapy consisted of 5-fluorouracil and either mitomycin C or cisplatin.
  • CONCLUSION: For HIV patients with anal carcinoma, CMT yields reasonable local control with significant acute complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. HIV Infections / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904522.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / 5P60-MD000525
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Yap JC, Yang GY, Fakih M, Mashtare T, Bullard Dunn K, Kuvshinoff BW, Smith J, Khushalani NI, Gibbs JF: Primary adenocarcinoma of the anus: a 22-year SEER population database analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e15072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the anus: a 22-year SEER population database analysis.
  • : e15072 Background: Most anal canal cancers consist of squamous cell carcinoma (SCCA).
  • Adenocarcinoma (AdenoCa) is rare and accounts for approximately 10% of anal cancers.
  • METHODS: The search of the SEER database revealed 1,008 pts who had pathologically confirmed anal cancers with either SCCA or AdenoCa.
  • All pts had single diagnosis of anal cancer with localized disease without nodal involvement.
  • Within the SCCA group, 14 (1.5%) had abdominoperineal resection (APR) in combination with external beam RT, and 795 (83.3%) had RT only with non-APR local surgical treatment inclusive of excision.
  • Remaining 145 SCCA pts (15.2%) had non-APR local surgical treatment only without RT or had no treatment.
  • Within the AdenoCa group, 10 (18.5%) had APR in combination with external beam RT, and 21 (38.9%) had RT only with non-APR local surgical treatment inclusive of excision.
  • Remaining 23 AdenoCa pts (42.6%) had non-APR local surgical treatment only without RT.
  • On the other hand, among the AdenoCa subset, pts who had APR had better 10-yr OS than RT pts (53.8% vs. 0%, p=0.03) Conclusions: For localized anal SCCA, RT yielded equivalent overall survival as compared to APR.
  • On the other hand, pts with localized anal adenoCa appeared to do worse when APR was omitted.
  • Omission of APR in pts with anal canal adenoCa should be cautiously weighed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964572.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. You YN, Larson DW, Dozois EJ, Nelson H, Antpack Filho E, Klein K, Miller RC: Multimodality salvage therapy for anal cancer failing standard chemoradiation. J Clin Oncol; 2009 May 20;27(15_suppl):e15635

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality salvage therapy for anal cancer failing standard chemoradiation.
  • : e15635 Background: Most squamous cell carcinomas of the anal canal (SCC) respond to chemoradiation, but effective therapy for locally-invasive(T4) or recurrent disease that fails standard chemoradiation and/or salvage abdominoperineal resection (APR) has not been clearly delineated.
  • Fifteen patients reported long-term complications (>grade3): bowel obstruction in 8 (1 requiring operation), perineal wound fistula/non-healing in 9, leg paresthesia in 5, hydronephrosis in 3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962742.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Nakao T: Micro RNA expression to predict side effects of preoperative chemoradiotherapy in rectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22211

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micro RNA expression to predict side effects of preoperative chemoradiotherapy in rectal cancer.
  • : e22211 Background: Preoperative chemoradiotherapy (CRT) in lower rectal cancer is used to prevent from local recurrence and preserve anus by avoiding to rectal amputation.
  • METHODS: Rectal cancer patients (n=22) who underwent preoperative CRT (40Gy radiotherapy combined with S- 1) were studied.
  • RNA harvested from biopsy specimens of rectal cancer before preoperative CRT was hybridized to miRNA microarrays (821 genes).
  • Groups were classified as side effect group (grade 3 or over) or non side effect group (group 0, 1, 2), respectively.
  • After CRT, 14 patients had PR (RR 63.6%) in RECIST and 15 patient had down staging in TMN classification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964166.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. James R, Wan S, Glynne-Jones R, Sebag-Montefiore D, Kadalayil L, Northover J, Cunningham D, Meadows H, Ledermann J, National Cancer Research Institute (NCRI) ACT II Trial Management Group: A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). J Clin Oncol; 2009 May 20;27(15_suppl):LBA4009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963297.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Gomez Rangel J Sr, Alvarez Ordorica O, Villalobos Valencia R, Silva JA: Utility of concomitant chemoradiotherapy with 5-fluorouracil (5-FU) single agent as neoadjuvant treatment regimen in mexican patients with stage III rectal cancer: Experience in the Oncology Hospital. J Clin Oncol; 2009 May 20;27(15_suppl):e15144

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of concomitant chemoradiotherapy with 5-fluorouracil (5-FU) single agent as neoadjuvant treatment regimen in mexican patients with stage III rectal cancer: Experience in the Oncology Hospital.
  • : e15144 Background: To analyze overall survival, free disease survival, complete and partial pathologic response, effect of stage reduction, toxicity profile and number of anus preservative surgery in patients treated with concurrent chemo radiotherapy with a modified 5-FU single agent regimen as neoadjuvant modality treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960884.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hammad N, Philip PA, Shields AF, Heilbrun LK, Venkatramanamoorthy R, El-Rayes BF: A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15586

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients.
  • : e15586 Background: Human immunodeficiency virus (HIV) infected patients (pts) are at increased risk for squamous cell carcinoma of the anal canal (SCCAC) and the incidence of SCCAC has increased in the era of HAART (highly active antiretroviral therapy).
  • The aim of this study is to describe the outcome, tolerability, and overall survival (OS) in pts with and without HIV infection treated at Karmanos Cancer Institute, at Wayne State University from 1991 to 2007.
  • We collected data regarding HIV status, demographics (age, gender, race), stage at diagnosis, treatment, response to treatment, toxicity, and survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962344.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Swampillai A, Williams M, Osborne M, Mawdsley S, Hughes R, Harrison M, Glynne-Jones R: A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT). J Clin Oncol; 2009 May 20;27(15_suppl):4117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT).
  • : 4117 Background: SCCAg is a tumour marker expressed by ECACM, measured by microparticle enzyme immunoassay; normal range 0-150ng/dl.
  • Radiotherapy comprised the schedule of the UK Anal cancer Trial (ACT II).
  • 30 had neo-adjuvant chemotherapy followed by CRT and 3 pts had planned surgery followed by CRT.
  • Clinical stage at diagnosis- Tx (6) T1 (28), T2 (80), T3 (65), T4 (16), N0 (126), N+ (66) Nx (3).
  • The mean baseline SCCAg for pts achieving CR was 408 and non CR was 513 (p = 0.13).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961219.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Subramonia Iyer S, Akl A: A review of the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry: 1987-2004. J Clin Oncol; 2009 May 20;27(15_suppl):e15131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry: 1987-2004.
  • : e15131 Background: This paper describes the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry.
  • The Hurley cancer registry was searched using diagnosis codes for anal cancer.
  • The records retrieved, were reviewed for demographic and pathologic details,cancer recurrence, and vital status at last follow up.
  • RESULTS: Over a period of 18 years (1987 - 2004), there were 36 patients enrolled in the registry, with a diagnosis of anal cancer.
  • Mean age at diagnosis was 59.3 (SD 17.6) years for males, and 64.6 (SD 13.8) years for females.
  • Squamous cell cancers were the most common: 27 / 36 (75%).
  • Three of the five (60%) recurrent cancers were associated with HIV infection.
  • Cumulative survival functions for the cohort were derived for the time points of 3-yrs and 5-yrs after diagnosis.
  • CONCLUSIONS: Among patients in the Hurley Cancer Registry, 1.
  • Squamous cell carcinoma is the commonest (75%) anal cancer.
  • 2. The risk of recurrence of anal cancer was 14% over 6-years, and 80% of recurrence was localised to the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960904.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Fakih MG, Pendyala L, Egorin MJ, Fetterly G, Espinoza-Delgado I, Ross M, Phelan J, Kramer Z, Yirinec B, Diasio R: A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):4083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pre-clinical studies demonstrate that vorinostat down-regulates intra-tumor TS in a dose-dependent fashion and augments 5-FU antitumor activity in xenograft models.
  • METHODS: Vorinostat was escalated in a standard 3 x 3 design in combination with a fixed dose of 5-FU and LV (simplified de Gramont regimen, sFULV2).
  • 21 pts had colorectal cancer (CRC), 1 had gastric, 1 had esophageal, and 1 had anal cancer.
  • Cycle 1 grade 3/4 toxicities consisted of thrombocytopenia, GI bleeding, fatigue, and H&F in 2 pts at the 2000 mg DL and a non-DLT G3 diarrhea (lasted <24 hrs) in 1 pt at the 1700 mg DL.
  • 12/21 CRC pts had a confirmed SD (11) or PR (1).
  • An expanded MTD cohort is accruing to investigate 5-FU-vorinostat PK interaction and intra-tumor TS down-regulation. (This work was supported by a grant from CTEP and the ACS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961640.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Eng C, Chang GJ, Das P, Rodriguez-Bigas M, Skibber JM, Qiao W, Rosner GL, Ukegbu LT, Wolff RA, Crane CH: Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. J Clin Oncol; 2009 May 20;27(15_suppl):4116

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal.
  • : 4116 Background: Definitive therapy for squamous cell carcinoma (SCC) of the anal canal consists of external beam radiotherapy with concurrent 5-fluorouracil and mitomycin C or cisplatin.
  • The purpose of this study was to evaluate the tolerability and efficacy of XELOX-XRT as definitive treatment for anal cancer.
  • METHODS: Patients with histologically proven SCC of the anal canal, AJCC Stage II-IIIB (T<sub>2-4</sub> or N+M<sub>0</sub>), ECOG PS 0-1, HIV<sup>-</sup>, and no prior therapy were eligible for XELOX-based chemoradiotherapy.
  • CONCLUSIONS: The combination of capecitabine, oxaliplatin, and radiation therapy (XELOX-XRT) is effective for locally advanced squamous cell carcinoma of the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961220.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Page BR, McDonald T, Gagnon P, Lu K, Thomas CR: A unique case of Hajdu-Cheney syndrome and squamous cell carcinoma of the anus. Colorectal Dis; 2009 Jun;11(5):535-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique case of Hajdu-Cheney syndrome and squamous cell carcinoma of the anus.
  • OBJECTIVE: Hajdu-Cheney syndrome (HCS), first described in 1948 by Hajdu and independently in 1965 by Cheney, is an extremely rare disorder characterized by severe and excessive bone resorption leading to osteoporosis, with a wide range of other systemic complications from connective tissue and bone dysplasia.
  • No articles exist in the current literature describing a case of HCS with concurrent carcinoma.
  • Here, we present a case of a 54-year-old nonimmune compromised woman with multiple stigmata of HCS and recently diagnosed anal squamous cell carcinoma.
  • METHOD: This is a case report of HCS and stage T3N0 squamous cell carcinoma of the anus.
  • CONCLUSIONS: We present a patient with HCS who developed anal squamous cell carcinoma.
  • The mechanism of HCS, which is still unknown, may either make patients more susceptible to carcinoma or may just be a reflection of the normal incidence of anal squamous cell carcinoma given attributable risk factors.
  • [MeSH-major] Anus Neoplasms / complications. Carcinoma, Squamous Cell / complications. Hajdu-Cheney Syndrome / complications


23. von Knebel Doeberitz M, Reuschenbach M: [Human papillomaviruses in the pathogenesis of intraepithelial neoplasia (AIN) and carcinoma of the anus]. Hautarzt; 2010 Jan;61(1):13-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human papillomaviruses in the pathogenesis of intraepithelial neoplasia (AIN) and carcinoma of the anus].
  • [Transliterated title] Humane Papillomviren in der Pathogenese der intraepithelialen Neoplasien (AIN) und Karzinome des Anus.
  • HPV infections have been implicated in the pathogenesis of anal cancers.
  • The mode of infection and subsequent transformation resembles very much the pathogenesis of cervical and other HPV-associated cancers.
  • The molecular dissection of individual steps required to achieve cellular transformation within an HPV-infected cell led to the identification of novel biomarkers that make it possible to identify HPV-transformed cells with substantially higher precision in comparison to conventional methods.
  • Since effective antiretroviral therapy allows for possible long-term survival of HIV-infected individuals who are at very high risk to develop HPV-associated cancers in the anogenital tract, these new developments have become increasingly relevant for practicing dermatologists and proctologists.
  • [MeSH-major] Anus Neoplasms / virology. Biomarkers, Tumor / analysis. Carcinoma in Situ / physiopathology. Papillomavirus Infections / diagnosis. Papillomavirus Infections / virology. Precancerous Conditions / virology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2007 Sep;131(9):1343-9 [17824788.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):58-66 [17186505.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3059-63 [15131043.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):795-801 [16819320.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3822-7 [16505361.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):307-13 [18172324.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1355-60 [15298958.001]
  • [Cites] Dis Markers. 2007;23(4):297-313 [17627064.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2435-8 [17294450.001]
  • [Cites] Dig Dis Sci. 2008 Mar;53(3):760-4 [17717741.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1107-14 [17548671.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):201-8 [14529682.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2229-42 [12441259.001]
  • [Cites] Virology. 2009 Feb 20;384(2):260-5 [19135222.001]
  • [Cites] Mol Diagn Ther. 2008;12(6):395-400 [19035626.001]
  • [Cites] Lancet Oncol. 2008 Oct;9(10):937-45 [18783988.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • [Cites] Arch Med Res. 2009 Aug;40(6):435-42 [19853183.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1299-307 [15520862.001]
  • [Cites] Lancet. 2007 Sep 8;370(9590):890-907 [17826171.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2307-13 [17029280.001]
  • [Cites] Acta Cytol. 2004 Nov-Dec;48(6):771-82 [15581161.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] J Low Genit Tract Dis. 2009 Jul;13(3):145-53 [19550211.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Nat Rev Cancer. 2007 Jan;7(1):11-22 [17186016.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):362-72 [15187189.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):396-403 [12845680.001]
  • [Cites] Hum Pathol. 2009 Nov;40(11):1517-27 [19716155.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 May;16(3):215-20 [18301250.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2536-45 [18842994.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Cancer. 2008 Apr 25;114(2):83-8 [18300235.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):35-40 [15790434.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4212-22 [12912919.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):616-20 [15480761.001]
  • (PMID = 20033115.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Franceschi S, De Vuyst H: Human papillomavirus vaccines and anal carcinoma. Curr Opin HIV AIDS; 2009 Jan;4(1):57-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus vaccines and anal carcinoma.
  • PURPOSE OF REVIEW: To explore the possible role of current prophylactic vaccines against human papillomavirus (HPV) in the prevention of anal intraepithelial neoplasia and squamous cell carcinoma of the anus (SCCA).
  • A meta-analysis of 955 SCCA showed that HPV prevalence was 85%, i.e., similar to that in cervical carcinoma, with an even stronger predominance of HPV16.
  • In addition, more than 90% prevalence of HPV was found in anal intraepithelial neoplasia.
  • Answers to some still open questions, notably vaccine efficacy in men and HIV-infected individuals and willingness to expand vaccination programmes to both sexes, are essential to predict the ultimate impact of HPV vaccines on the prevention of cancerous and precancerous anal lesions.
  • [MeSH-major] Anus Neoplasms / prevention & control. Carcinoma in Situ / prevention & control. Carcinoma, Squamous Cell / prevention & control. HIV Infections / complications. Papillomavirus Infections / prevention & control. Papillomavirus Vaccines / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19339940.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Papillomavirus Vaccines
  • [Number-of-references] 56
  •  go-up   go-down


25. Newsom-Davis T, Bower M: HIV-associated anal cancer. F1000 Med Rep; 2010;2:85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated anal cancer.
  • HIV-associated anal carcinoma, a non-AIDS-defining cancer, is a human papillomavirus-associated malignancy with a spectrum of preinvasive changes.
  • The standardized incidence ratio for anal cancer in patients with HIV/AIDS is 20-50.
  • Algorithms for anal cancer screening include anal cytology followed by high-resolution anoscopy for those with abnormal findings.
  • Outpatient topical treatments for anal intraepithelial neoplasia include infrared coagulation therapy, trichloroacetic acid, and imiquimod.
  • The development of cost-effective national screening programs for HIV-associated anal cancer remains a challenge.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1992 Apr 8;267(14):1892 [1548812.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):293-9 [15980688.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1054-60 [17714124.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] Int J STD AIDS. 2008 Feb;19(2):118-20 [18334066.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] J Public Health (Oxf). 2008 Sep;30(3):293-304 [18559368.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):474-9 [19779306.001]
  • [Cites] AIDS. 2010 Feb 20;24(4):535-43 [19926961.001]
  • [Cites] Br J Dermatol. 2010 Jun;162(6):1269-77 [20184584.001]
  • [Cites] AIDS. 2010 Jun 1;24(9):1307-13 [20442633.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] AIDS. 2004 Jul 23;18(11):1561-9 [15238774.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):782-5 [3652891.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand A. 1986 Sep;94(5):343-9 [3766143.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] Sex Transm Infect. 2005 Apr;81(2):142-6 [15800092.001]
  • (PMID = 21283597.001).
  • [ISSN] 1757-5931
  • [Journal-full-title] F1000 medicine reports
  • [ISO-abbreviation] F1000 Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3026623
  •  go-up   go-down


26. Lund JA, Wibe A, Sundstrom SH, Haaverstad R, Kaasa S, Myrvold HE: Anal carcinoma in mid-Norway 1970-2000. Acta Oncol; 2007;46(7):1019-26
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in mid-Norway 1970-2000.
  • The treatment of anal carcinoma changed from surgery to chemoradiotherapy 20-25 years ago.
  • The aim of this observational study was to compare surgery with chemoradiotherapy with regard to side effects, local recurrence and survival during and after the implementation of a new treatment policy for anal carcinoma.
  • The study includes all 111 patients with anal carcinoma diagnosed between 1970 and 2000 in mid-Norway.
  • Late side effects were moderate after combined therapy; only one patient preferred getting a stoma due to radiation damage of the anal sphincter.
  • The change of strategy for anal cancer treatment from surgery to combined therapy has probably reduced local recurrence and improved survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882558.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


27. van Lieshout A, Pronk A: [Increasing incidence of anal cancer in the Netherlands]. Ned Tijdschr Geneeskd; 2010;154:A1163
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Increasing incidence of anal cancer in the Netherlands].
  • Anal cancer is a rare malignancy with a rapidly rising incidence.
  • The most important risk factor for anal cancer is persistent infection with Human papillomavirus (HPV).
  • In the Netherlands, the incidence of anal cancer increased from 71 to 149 new patients each year over the period 1989-2006.
  • Not enough research has been done to date to clarify why the incidence of anal cancer is increasing.
  • [MeSH-major] Anus Neoplasms / epidemiology. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20456793.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 11
  •  go-up   go-down


28. Dahl O, Fluge Ø: [Anal cancer]. Tidsskr Nor Laegeforen; 2008 Jan 17;128(2):198-200
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer].
  • [Transliterated title] Analkreft.
  • BACKGROUND: Anal cancer is a rare condition in Norway (40-50 new cases annually).
  • Knowledge of symptoms and findings is a prerequisite for providing a diagnosis while it is still possible to offer effective treatment with minimal side effects.
  • RESULTS AND INTERPRETATION: General practitioners must routinely examine patients with symptoms from the anal region in order to distinguish anal cancer from common haemorrhoids.
  • Diagnosis and treatment is centralized to cancer clinics at the Universities.
  • The main treatment modality is radiation therapy combined with chemotherapy, while surgery is relevant when the tumour is not controlled or for local side effects.
  • [MeSH-major] Anus Neoplasms

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202733.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 31
  •  go-up   go-down


29. Panther LA, Schlecht HP, Dezube BJ: Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients. AIDS Read; 2005 Feb;15(2):79-82, 85-6, 88, 91
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients.
  • The incidence of human papillomavirus (HPV)-related anal squamous cell carcinoma is increasing.
  • It is likely that long-standing HIV-related immunosuppression plays a significant role in the pathogenesis of anal carcinoma; however, a direct HIV-HPV interaction has also been implicated.
  • Using cervical cancer prevention as a paradigm, anal Pap smear screening as part of routine HIV preventive care has been proposed to detect and treat precancerous anal lesions in the hope of decreasing anal cancer rates.
  • All HIV-positive patients with invasive cancer of the anal canal, particularly those with CD4+ cell counts greater than 200/microL and those receiving HAART, should be managed in the same manner as their HIV-negative counterparts.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. HIV Infections / epidemiology. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Precancerous Conditions / pathology


30. Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2656-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
  • He presented with an anal tumor with bilateral inguinal nodal metastasis and pain in the anus; the tumor was diagnosed as stage IIIb (cA1N2M0).
  • However, CT performed 2 years after the diagnosis showed a recurrence in the hilar and mediastinal lymph node.
  • The patient developed non-hematologic toxicity and died within 3 years of the diagnosis.
  • We report a case of squamous cell carcinoma of the anus with associated HIV infection.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications


31. Palefsky JM: Anal cancer prevention in HIV-positive men and women. Curr Opin Oncol; 2009 Sep;21(5):433-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer prevention in HIV-positive men and women.
  • PURPOSE OF REVIEW: The incidence of human papillomavirus-associated anal cancer is unacceptably high among HIV-positive men who have sex with men, and possibly in HIV-positive women.
  • Unlike most other malignancies occurring in the HIV-positive population, anal cancer is potentially preventable, using methods similar to those used to prevent cervical cancer in women.
  • This review discusses the issues around screening to prevent anal cancer.
  • RECENT FINDINGS: Recent studies show that the incidence of anal cancer has increased since the introduction of highly active antiretroviral therapy in this population and now exceeds the highest incidence of cervical cancer among women reported anywhere in the world.
  • SUMMARY: The high incidence of anal cancer among HIV-positive individuals must not be ignored, since it may be preventable.
  • Given the current evidence and analogy with the cervical cancer prevention model, many clinicians believe that identification and treatment of high-grade anal intraepithelial neoplasia to prevent anal cancer are warranted.
  • When the expertise to do so exists, this is a reasonable approach, particularly if coupled with efforts to optimize further screening and treatment approaches, as well as efforts to document the efficacy of high-grade anal intraepithelial neoplasia treatment to reduce the incidence of anal cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):474-9 [19779306.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-70 [17602732.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] Dis Colon Rectum. 2009 Feb;52(2):239-47 [19279418.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] Br J Dermatol. 2009 Oct;161(4):904-9 [19466962.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • (PMID = 19587592.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCI NIH HHS / CA / CA088739-04S2; United States / NCI NIH HHS / CA / CA054053-10; United States / NCI NIH HHS / CA / R01 CA054053; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / R01 CA088739; United States / NCI NIH HHS / CA / R01 CA088739-04S2; United States / NCRR NIH HHS / RR / M01 RR00079; United States / NCI NIH HHS / CA / R01CA 88739; United States / NCI NIH HHS / CA / R01 CA054053-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  • [Other-IDs] NLM/ NIHMS202771; NLM/ PMC3415247
  •  go-up   go-down


32. Durães Lde C, Sousa JB: [Anal cancer and sexually transmitted diseases: what is the correlation?]. Rev Col Bras Cir; 2010 Aug;37(4):265-8
MedlinePlus Health Information. consumer health - Sexually Transmitted Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer and sexually transmitted diseases: what is the correlation?].
  • [Transliterated title] Câncer anal e doenças sexualmente transmissíveis: qual a correlação?
  • OBJECTIVE: Anal cancer is a rare tumor, which incidence is influenced by sexual behavior.
  • The purpose of this paper is to verify the correlation between anal cancer and sexually transmitted diseases, such as HPV, HIV, Gonococci infection, Chlamydia infection, syphilis and others.
  • METHODS: All the internments due to anal cancer, HIV, HPV, syphilis, Gonococci infection, Chlamydia infection and other sexually transmitted diseases in public healthy in Brazil were collected at Datasus site between 1998 and 2007.
  • RESULTS: There was a high correlation between anal cancer and HPV admissions (r=0.98, p<0.001).
  • There was negative correlation between anal cancer and Gonococci infection admissions (r=-0.81, p=0.005) and anal cancer and Chlamydia infection (r=-0.74, p=0.014).
  • There was not statistic significant correlation between anal cancer and HIV admissions (r=0.40, p=0.245), between anal cancer and other sexually transmitted diseases (r=0.55, p=0.1), and between anal cancer and syphilis (r=-0.61, p=0.059).
  • CONCLUSION: There was a high positive correlation between anal cancer and HPV admissions in Brazil.
  • There were negative correlations between anal cancer and Gonococci infection and between anal cancer and Chlamydia infection admissions.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / epidemiology. Sexually Transmitted Diseases / complications. Sexually Transmitted Diseases / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21085842.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


33. Moe MM, Askill C: Stridor: an unexpected complication from chemoradiotherapy for anal cancer. J R Coll Physicians Edinb; 2009 Dec;39(4):313-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stridor: an unexpected complication from chemoradiotherapy for anal cancer.
  • The treatment of choice for anal cancer is chemoradiotherapy.
  • We report a patient who developed stridor as a result of chemoradiotherapy for anal cancer and discuss the pathogenesis and potential consequences.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21152467.001).
  • [ISSN] 1478-2715
  • [Journal-full-title] The journal of the Royal College of Physicians of Edinburgh
  • [ISO-abbreviation] J R Coll Physicians Edinb
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


34. Mariani P, Ghanneme A, De la Rochefordière A, Girodet J, Falcou MC, Salmon RJ: Abdominoperineal resection for anal cancer. Dis Colon Rectum; 2008 Oct;51(10):1495-501
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominoperineal resection for anal cancer.
  • PURPOSE: Following initial radiotherapy or chemoradiotherapy for the treatment of anal cancer, patients who present with either persistent or locally recurrent disease are treated by abdominoperineal resection.
  • METHODS: Over a 34-year period (1969-2003), 422 patients with nonmetastatic anal cancer were treated with a curative intent.
  • Using univariate analysis, patients below 55 years, females, T1-2 tumors, N0-N1 lymphadenopathy and the absence of locally advanced tumor were associated with significantly improved survival.
  • CONCLUSIONS: Abdominoperineal resection for nonmetastatic anal cancer is associated with a high morbidity rate but may result in long-term survival regardless of the indication.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Perineum / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521675.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Dandapani SV, Eaton M, Thomas CR Jr, Pagnini PG: HIV- positive anal cancer: an update for the clinician. J Gastrointest Oncol; 2010 Sep;1(1):34-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV- positive anal cancer: an update for the clinician.
  • Anal cancer used to be a rare cancer traditionally associated with elderly women.
  • The onslaught of the Human Immunodeficiency Virus (HIV) virus has led to a change in anal cancer demographics.
  • Anal cancer is on the rise in the U.S and the number of anal cases documented has quadrupled in the past 20 yrs correlating with the rise of the HIV epidemic.
  • The incidence of anal cancer is 40 to 80 fold higher in the HIV positive (HIV+) population when compared to the general population (2).
  • As a consequence non AIDS defining cancers such as anal cancer are on the rise.
  • Factors implicated in the etiology of anal cancer in HIV+ patients include (Human papillomavirus) HPV virus status, sexual habits, and a history of smoking.
  • HPV 16 and receptive anal intercourse (RAI) increase the risk of anal cancer by 33% over the general population.
  • In the general population, the rate of anal cancer is approximately 0.9 cases per 100,000.
  • In patients with a history of RAI, the rate approaches 35 cases per 100,000 which is equivalent to the prevalence of cervical cancer (3).
  • Smokers are eight times more likely to develop anal cancer.
  • There has been much discussion about tailoring treatment decisions in HIV+ patients with anal cancer.
  • This review focuses on squamous cell carcinomas of the anal canal which comprise 80 to 90% of all anal cancers diagnosed and highlight key issues in the management of HIV+ anal cancer patients including recent clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Med Assoc. 1992 Feb;84(2):165-76 [1602515.001]
  • [Cites] Br J Dermatol. 2010 Jun;162(6):1269-77 [20184584.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):861-5 [8076484.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1176-81 [15906137.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Radiat Oncol. 2006;1:29 [16916475.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):2-9 [18030528.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] Dis Colon Rectum. 2008 Feb;51(2):147-53 [18180997.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2699-706 [18509182.001]
  • [Cites] Curr Opin Oncol. 2008 Sep;20(5):534-40 [19106656.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):143-9 [19203845.001]
  • [Cites] Hum Pathol. 2009 Nov;40(11):1517-27 [19716155.001]
  • [Cites] Radiother Oncol. 2009 Nov;93(2):298-301 [19717198.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1425-32 [19744801.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):474-9 [19779306.001]
  • [Cites] Diagn Cytopathol. 2010 Jul;38(7):538-46 [19941374.001]
  • [Cites] Sex Transm Dis. 2010 May;37(5):311-5 [20065890.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1413-9 [20231064.001]
  • [Cites] Br J Cancer. 2010 Mar 30;102(7):1123-8 [20354531.001]
  • [Cites] AIDS. 2010 Apr 24;24(7):1085-6; author reply 1086-7 [20386381.001]
  • [Cites] Hematol Oncol Clin North Am. 2010 Jun;24(3):567-75 [20488354.001]
  • [Cites] Oncology (Williston Park). 2010 Aug;24(9):828, 830-1 [20923036.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer J Sci Am. 1996 Jul-Aug;2(4):205-11 [9166533.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1488-93 [9860327.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):690-8 [11357031.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1496-502 [11598480.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5230-5 [12234989.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):859-72 [12852659.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1305-9 [15484343.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61 [16168830.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):206-11 [16904522.001]
  • [Cites] Dis Colon Rectum. 2009 May;52(5):891-7 [19502853.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1152-9 [19818686.001]
  • [Cites] Curr Probl Cancer. 2009 Sep-Oct;33(5):302-26 [20082844.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • (PMID = 22811803.001).
  • [ISSN] 2219-679X
  • [Journal-full-title] Journal of gastrointestinal oncology
  • [ISO-abbreviation] J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3397564
  • [Keywords] NOTNLM ; Anal canal / Anal cancer / HIV
  •  go-up   go-down


36. Ramamoorthy S, Liu YT, Luo L, Miyai K, Lu Q, Carethers JM: Detection of multiple human papillomavirus genotypes in anal carcinoma. Infect Agent Cancer; 2010;5:17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of multiple human papillomavirus genotypes in anal carcinoma.
  • Infection with human papillomavirus (HPV) is a major risk factor for development of anal squamous cell carcinoma.
  • Despite over 100 genotypes of the virus, HPV 16 and 18 are considered pathogenic as they are seen in the majority of cervical and anal cancers.
  • We aimed to determine the accuracy of our microarray in anal cancer DNA for HPV genotypes compared to the DNA sequencing gold standard.
  • METHODS: We utilized a sensitive microarray platform to classify 37 types of mucosal HPVs including 14 known high-risk and 23 low-risk types based on cervical cancer data.
  • We utilized DNA from pathologically confirmed cases of anal squamous cell carcinoma.
  • RESULTS: HPV was detected in 18/20 (90%) anal cancers.
  • Eighty percent of anal cancers had at least two HPV types.
  • CONCLUSIONS: Microarray technology is an accurate way to screen for various genotypes of HPV in anal cancer, with 100% correlation with genomic DNA detection of HPV.
  • The majority of anal cancers in our study associated with pathogenic HPV 16 and/or 18.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939896.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067287; United States / NCI NIH HHS / CA / R21 CA137346; United States / NIDDK NIH HHS / DK / R24 DK080506
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2964599
  •  go-up   go-down


37. Herat A, Whitfeld M, Hillman R: Anal intraepithelial neoplasia and anal cancer in dermatological practice. Australas J Dermatol; 2007 Aug;48(3):143-53; quiz 154-5
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia and anal cancer in dermatological practice.
  • Anal intraepithelial neoplasia is considered to be a precursor lesion of invasive anal cancer.
  • Human papillomaviruses are considered to be an important aetiological agent in both anal intraepithelial neoplasia and anal cancer.
  • Dermatologists are likely to encounter these conditions among the differential diagnoses to be considered in high-risk patients presenting with perianal and anal lesions.
  • Anal cancer rates are also increasing among the HIV-infected and HIV-non-infected population.
  • The successful treatment of anal intraepithelial neoplasia may reduce the risk of subsequent development of anal cancer.
  • However, current therapies for anal intraepithelial neoplasia may be associated with treatment-related morbidity and are not well validated.
  • It is currently not proven that they reduce the likelihood of the development of anal cancer.
  • Nevertheless, screening for anal intraepithelial neoplasia is being advocated for high-risk groups and may become standard dermatological care for these patients.
  • In view of recent developments in the understanding of this condition, this article reviews the current understanding of anal intraepithelial neoplasia and its treatment from a dermatological perspective.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Carcinoma, Squamous Cell. Papillomavirus Infections
  • [MeSH-minor] Diagnosis, Differential. HIV Infections / complications. Humans. Papillomaviridae / pathogenicity

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680964.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 115
  •  go-up   go-down


38. Wilkes G, Hartshorn K: Colon, rectal, and anal cancers. Semin Oncol Nurs; 2009 Feb;25(1):32-47
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon, rectal, and anal cancers.
  • OBJECTIVES: To review the incidence, risk factors, staging, diagnosis, and treatment of colon, rectal, and anal cancers, as well as nursing care associated with managing patients diagnosed with these malignancies.
  • CONCLUSIONS: Significant advances in the management of colon, rectal, and anal cancers in the past decade have extended patient survival.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell. Colonic Neoplasms. Rectal Neoplasms
  • [MeSH-minor] Humans. Neoplasm Staging. Risk Factors

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19217504.001).
  • [ISSN] 0749-2081
  • [Journal-full-title] Seminars in oncology nursing
  • [ISO-abbreviation] Semin Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


39. D'Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, Jacobson LP: Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr; 2008 Aug 1;48(4):491-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study.
  • OBJECTIVE: To examine the incidence and risk factors for anal cancer in a multicenter cohort of human immunodeficiency virus (HIV) positive and HIV-negative men who have sex with men followed between 1984 and 2006 (Multicenter AIDS Cohort Study).
  • RESULTS: There were 28 cases of anal cancer among the 6,972 men who were evaluated.
  • Among HIV-positive men, anal cancer incidence was higher in the highly active antiretroviral therapy (HAART) era than the pre-HAART era (incidence rate = 137 vs 30 per 100,000 person-years).
  • In multivariate analysis restricted to the HAART era, anal cancer risk increased significantly with HIV infection (relative hazard = 4.7, 95% confidence interval = 1.3 to 17) and increasing number of unprotected receptive anal sex partners at the first 3 study visits (P trend = 0.03).
  • Among HIV-positive men, current HAART use did not decrease anal cancer risk.
  • CONCLUSIONS: HIV-positive men had increased risk of anal cancer.
  • Improved survival of HIV-positive individuals after HAART initiation may allow for sufficient time for human papillomavirus-associated anal dysplasias to develop into malignancies, thus explaining the increased incidence of anal cancer in the HAART era.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] HIV Clin Trials. 2000 Jul-Aug;1(1):60-110 [11590490.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):20-8 [12807941.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] Clin Immunol Immunopathol. 1990 May;55(2):173-86 [1969782.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] MMWR CDC Surveill Summ. 1992 Apr 24;41(2):1-7 [1594012.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 [7966400.001]
  • [Cites] Am J Epidemiol. 1995 Aug 1;142(3):323-30 [7631636.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Am J Epidemiol. 1996 Nov 15;144(10):916-23 [8916502.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 15;18(5):495-504 [9715847.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] J Natl Med Assoc. 2007 Dec;99(12):1386-94 [18229775.001]
  • [Cites] J Adolesc Health. 1999 Nov;25(5):328-35 [10551663.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):843-9 [11390533.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S42-8 [10430218.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2862-7 [15837733.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Colorectal Dis. 2005 Sep;7(5):492-5 [16108887.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):62-6 [16374220.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Am J Public Health. 2006 Jun;96(6):1020-7 [16670218.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10 [16949995.001]
  • [Cites] Infect Dis Obstet Gynecol. 2006;2006 Suppl:40470 [16967912.001]
  • [Cites] AIDS Alert. 2006 Mar;21(3):22-3 [17378064.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • (PMID = 18614927.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NIAID NIH HHS / AI / UO1-AI-37984; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NCRR NIH HHS / RR / 5-MO1-RR-00722; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NIAID NIH HHS / AI / UO1-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-37613
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS562648; NLM/ PMC3991563
  •  go-up   go-down


40. Allison RR, Sheng C, Cuenca R, Bagnato VS, Austerlitz C, Sibata CH: Photodynamic therapy for anal cancer. Photodiagnosis Photodyn Ther; 2010 Jun;7(2):115-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for anal cancer.
  • Invasive anal cancers are generally successfully treated by combined chemotherapy with radiation therapy (XRT).
  • We examined the treatment and outcome of Photofrin based photodynamic therapy (PDT) in a cohort of patients with anal cancer who failed locally despite chemo-radiation (N=6) and two patients with positive margins of resection after excision of small T(1) squamous cell anal cancers who refused further surgery or chemo-radiation.
  • Red light (630 nm) illumination was delivered by a 5 cm diffusing fiber, treating transphincterally at 300 J/cm followed by microlens illumination at 200 J/cm(2) to the perianal tumor bed with 2 cm margin.
  • All patients completed PDT without incident and all have maintained local control of disease in the anal region for the length of follow up (18-48 months).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20510306.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  • [Number-of-references] 22
  •  go-up   go-down


41. Sato H, Maeda K, Koide Y, Matsuoka H, Noro T, Honda K, Shiota M, Endo T, Ozeki S, Fukuda M: [Four cases of anal squamous cell carcinoma treated by chemoradiotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2647-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Four cases of anal squamous cell carcinoma treated by chemoradiotherapy].
  • We reviewed clinical records of 4 cases with squamous cell carcinoma in anus to evaluate the clinical effectiveness of the chemoradiotherapy.
  • Three patients had T2 tumor, and one patient had T1 tumor.
  • All patients had complete response in the anal lesion after chemoradiotherapy.
  • No patients had any sign of recurrence in anal lesion.
  • Chemoradiotherapy was expected to be a safe and effective treatment to improve prognosis for anal squamous carcinoma.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224667.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. Eng C: Anal cancer: current and future methodology. Cancer Invest; 2006 Aug-Sep;24(5):535-44
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: current and future methodology.
  • Despite the small number of patients affected by carcinoma of the anal canal it remains one of the most challenging cancers to treat.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Clinical Trials as Topic. Fluorouracil / therapeutic use. HIV Infections / complications. Humans. Mitomycin / therapeutic use. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm, Residual. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939964.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 64
  •  go-up   go-down


43. Robb BW, Mutch MG: Epidermoid carcinoma of the anal canal. Clin Colon Rectal Surg; 2006 May;19(2):54-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid carcinoma of the anal canal.
  • Anal cancers are rare tumors with only an expected 4000 new diagnoses in 2005.
  • The majority of these are epidermoid or squamous cell cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1153-60 [2599903.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Br J Surg. 2005 May;92(5):605-14 [15739215.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Cancer. 1956 May-Jun;9(3):480-8 [13329997.001]
  • [Cites] Arch Surg. 1964 Dec;89:989-94 [14208473.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] Acta Oncol. 1997;36(8):799-802 [9482685.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):405-9 [10430247.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1488-93 [9860327.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1300-2 [9731737.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Br J Cancer. 1997;75(5):722-8 [9043031.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1996;8(5):319-22 [8934052.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Pathol. 1996 Dec;180(4):378-82 [9014857.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1569-79 [8156483.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 [7966400.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):300-2 [8022440.001]
  • [Cites] Obstet Gynecol. 1994 Feb;83(2):205-11 [8290181.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1385-7 [1938540.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Arch Surg. 1992 Jun;127(6):741-4 [1317698.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] N Engl J Med. 1986 Oct 23;315(17):1089-90 [3020406.001]
  • [Cites] Am J Clin Pathol. 1989 Jul;92(1):16-21 [2546419.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):806-10 [2765832.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] J Infect Dis. 1990 Aug;162(2):358-61 [1973695.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] Br J Cancer. 1983 Nov;48(5):629-36 [6639856.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1425-9 [12390386.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1496-502 [11598480.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1141-51 [2599902.001]
  • (PMID = 20011311.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780104
  • [Keywords] NOTNLM ; Epidermoid cancer / anal canal / squamous cancer
  •  go-up   go-down


44. Contu SS, Agnes G, Damin AP, Contu PC, Rosito MA, Alexandre CO, Damin DC: Lack of correlation between p53 codon 72 polymorphism and anal cancer risk. World J Gastroenterol; 2009 Sep 28;15(36):4566-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of correlation between p53 codon 72 polymorphism and anal cancer risk.
  • AIM: To investigate the potential role of p53 codon 72 polymorphism as a risk factor for development of anal cancer.
  • METHODS: Thirty-two patients with invasive anal carcinoma and 103 healthy blood donors were included in the study. p53 codon 72 polymorphism was analyzed in blood samples through polymerase chain reaction-restriction fragment length polymorphism and DNA sequencing.
  • RESULTS: The relative frequency of each allele was 0.60 for Arg and 0.40 for Pro in patients with anal cancer, and 0.61 for Arg and 0.39 for Pro in normal controls.
  • CONCLUSION: These results do not support a role for the p53 codon 72 polymorphism in anal carcinogenesis.
  • [MeSH-major] Anus Neoplasms / genetics. Genes, p53

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Aug;67(2):444-61 [10873790.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1037-42 [11045785.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):565-6 [11352871.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):782-6 [11787851.001]
  • [Cites] Cancer Lett. 2002 May 28;179(2):175-83 [11888672.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):721-8 [12354793.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Am J Hum Biol. 2003 Nov-Dec;15(6):824-34 [14595874.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):196-9 [14639602.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):131-5 [14734461.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):11-22 [14744727.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):131-7 [14999143.001]
  • [Cites] Int J Gynaecol Obstet. 2004 Jun;85(3):301-8 [15145278.001]
  • [Cites] Mol Cell Biol. 1986 Dec;6(12):4650-6 [3025664.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]
  • [Cites] Science. 1990 Apr 6;248(4951):76-9 [2157286.001]
  • [Cites] Nucleic Acids Res. 1990 Aug 25;18(16):4961 [1975675.001]
  • [Cites] Hum Hered. 1994 Sep-Oct;44(5):266-70 [7927355.001]
  • [Cites] Hum Hered. 1995 May-Jun;45(3):144-9 [7615299.001]
  • [Cites] Hum Hered. 1996 Jan-Feb;46(1):41-8 [8825462.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] Nature. 1998 May 21;393(6682):229-34 [9607760.001]
  • [Cites] J Mol Med (Berl). 1999 Feb;77(2):299-302 [10023783.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jun;159(2):143-7 [15899386.001]
  • [Cites] Am J Hum Biol. 2005 Jul-Aug;17(4):496-506 [15981186.001]
  • [Cites] Cancer Detect Prev. 2006;30(6):523-9 [17113725.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Eur J Surg Oncol. 2007 Jun;33(5):569-74 [17321098.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):621-32 [17405118.001]
  • [Cites] Oral Oncol. 2008 Aug;44(8):798-804 [18234542.001]
  • [Cites] Oncol Rep. 2009 Mar;21(3):809-14 [19212643.001]
  • [Cites] Mol Cell Biol Res Commun. 2000 Jun;3(6):389-92 [11032762.001]
  • (PMID = 19777616.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Codon
  • [Other-IDs] NLM/ PMC2752002
  •  go-up   go-down


45. Gervaz P, Buchs N, Morel P: Diagnosis and management of anal cancer. Curr Gastroenterol Rep; 2008 Oct;10(5):502-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of anal cancer.
  • During the past three decades, anal cancer has served as a paradigm for the successful application of chemoradiation to solid tumors.
  • Since the early 1990s, the increasing incidence of anal cancer in homosexual men has highlighted the causative role of oncogenic human papilloma-virus infection.
  • This review focuses on significant trends and developments in the management of patients with squamous cell carcinoma of the anal canal, emphasizing three major aspects of diagnosis and treatment: routine screening and eradication of premalignant lesions in high-risk individuals; outcome of chemoradiation therapy in HIV-positive individuals in the era of highly active antiretroviral therapy; and potential improvements in chemoradiation protocols through improved radiation delivery technique and the combination of mitomycin with cisplatin in current prospective randomized trials.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sex Transm Infect. 2005 Apr;81(2):142-6 [15800092.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):1024-30; discussion 1031 [15585390.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2780-9 [17638059.001]
  • [Cites] Radiat Oncol. 2006 Aug 18;1:29 [16916475.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):277-90 [15736144.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Dis Colon Rectum. 2008 Feb;51(2):147-53 [18180997.001]
  • [Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4516-7 [16983122.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1470-5 [18299937.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Transpl Int. 2007 Jun;20(6):497-504 [17343685.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):474-9 [18202423.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1176-81 [15906137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1394-400 [17276620.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):570-4 [16919108.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):87-90 [16721368.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1496-502 [11598480.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Colorectal Dis. 2006 Feb;8(2):124-9 [16412072.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1410-5; discussion 1415-6 [17710507.001]
  • [Cites] Dis Colon Rectum. 2007 Jan;50(1):43-9 [17089083.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] AIDS. 2006 May 12;20(8):1151-5 [16691066.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] Dis Colon Rectum. 1981 Mar-Apr;24(2):73-5 [7215078.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1744-51 [17846856.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1133-6 [16044425.001]
  • [Cites] Lancet. 2007 May 19;369(9574):1693-702 [17512854.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • (PMID = 18799127.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


46. Abramowitz L, Rémy V, Vainchtock A: Economic burden of anal cancer management in France. Rev Epidemiol Sante Publique; 2010 Oct;58(5):331-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Economic burden of anal cancer management in France.
  • BACKGROUND: The incidence of anal cancer has increased over the last 25 years.
  • No organized screening exists for the precursors of anal cancer (anal intraepithelial neoplasia and carcinoma in situ) and diagnosis is often delayed.
  • Treatment for precursor lesions is of limited success, while cancer management is traumatic for the patient.
  • Like cancers of the cervix, most cases of anal cancer are associated with infection with human papillomavirus (HPV).
  • With increases in the incidence of anal cancer, and in light of the availability of prevention strategies such as screening and HPV vaccination, it is important, from a public health perspective, to assess the economic burden of anal cancer in France.
  • METHODS: We performed a retrospective analysis based on data extracted from a French hospital database - the Programme de médicalisation des systèmes d'information (PMSI) - to assess the number and management of patients hospitalized for anal cancer in 2006.
  • Data on radiotherapy sessions performed in private hospitals were obtained from the Statistiques annuelles des établissements de santé (SAE) database.
  • Costs of hospitalization, from the healthcare-payer perspective, were obtained from official diagnosis-related group tariffs for public and private hospitals.
  • RESULTS: In 2006, 3,711 patients with anal cancer were treated in hospitals in France.
  • The annual cost of hospital treatment for anal cancer was estimated at € 20,326,868.
  • CONCLUSION: This study, the first to investigate the economic burden of anal cancer in France, shows that the management costs of anal cancer are high and comparable to cervical cancer management costs (€ 44 million).
  • [MeSH-major] Anus Neoplasms / economics. Health Care Costs

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20869182.001).
  • [ISSN] 0398-7620
  • [Journal-full-title] Revue d'épidémiologie et de santé publique
  • [ISO-abbreviation] Rev Epidemiol Sante Publique
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


47. Goéré D, Bonnet S, Pocard M, Deutsch E, Lasser P, Elias D: Oncologic and functional results after abdominoperineal resection plus pseudocontinent perineal colostomy for epidermoid carcinoma of the anus. Dis Colon Rectum; 2009 May;52(5):958-63
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncologic and functional results after abdominoperineal resection plus pseudocontinent perineal colostomy for epidermoid carcinoma of the anus.
  • PURPOSE: Surgical treatment for epidermoid carcinoma of the anus is reserved for patients after failure of primary chemoradiotherapy and consists of abdominoperineal resection with permanent iliac colostomy.
  • The purpose of this study was to analyze the oncologic and the functional outcomes after abdominoperineal resection and pseudocontinent perineal colostomy for epidermoid carcinoma of the anus after external radiation at maximal doses (60 Gy).
  • METHODS: Between 1990 and 2006, 95 patients underwent abdominoperineal resection for an epidermoid carcinoma of the anus.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Colostomy / methods. Perineum / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502862.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Poggi MM, Suh WW, Saltz L, Konski AA, Mohiuddin M, Herman J, Johnstone PA: ACR Appropriateness Criteria on treatment of anal cancer. J Am Coll Radiol; 2007 Jul;4(7):448-56
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACR Appropriateness Criteria on treatment of anal cancer.
  • Anal cancer is a relatively rare neoplasm, accounting for roughly 4,500 cases per year.
  • The evolution of the definitive treatment of anal cancer from a surgical to a nonsurgical approach, however, has been viewed as a model disease site in a larger paradigm shift in medicine.
  • Organ preservation, in this case a functional anal sphincter, and durable cure are obtainable goals.
  • To this end, anal cancer is a disease best treated primarily with chemoradiation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Mitomycin / therapeutic use. Neoplasm Staging. Predictive Value of Tests

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601586.001).
  • [ISSN] 1558-349X
  • [Journal-full-title] Journal of the American College of Radiology : JACR
  • [ISO-abbreviation] J Am Coll Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


49. Rödel C: [Radiochemotherapy for locally advanced anal cancer]. Onkologie; 2010;33 Suppl 4:24-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiochemotherapy for locally advanced anal cancer].
  • [Transliterated title] Radiochemotherapie des lokal fortgeschrittenen Analkarzinoms.
  • Standard treatment for anal canal cancer is definitive radiochemotherapy (RCT) with 5-fluorouracil plus mitomycin C.
  • Because anal cancer overexpresses the epidermal growth factor receptor (EGFR), and a KRAS wild type is usually present, treatment with the EGFR antibody cetuximab is potentially interesting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Neoadjuvant Therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Cetuximab. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Clinical Trials as Topic. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Staging. Prognosis. Proto-Oncogene Proteins / genetics. Radiotherapy, Adjuvant. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431309.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 50SG953SK6 / Mitomycin; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 13
  •  go-up   go-down


50. Sendagorta E, Herranz P, Guadalajara H, Zamora FX, Gonzalez J: Anal carcinoma in an HIV-infected woman. ScientificWorldJournal; 2010;10:986-7
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in an HIV-infected woman.
  • A 42-year-old HIV-infected woman with an antecedent of HPV-related genital disease is diagnosed with invasive anal carcinoma due to HPV 16.
  • Anal cancer is becoming an increasing problem in HIV-infected woman.
  • In fact, the prevalence of HPV infection-related disease in this population is higher in the anus than in the cervix.
  • [MeSH-major] Anus Neoplasms / complications. HIV Infections / complications. Papillomavirus Infections / complications. Tumor Virus Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526528.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Das P, Crane CH, Ajani JA: Current treatment for localized anal carcinoma. Curr Opin Oncol; 2007 Jul;19(4):396-400
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment for localized anal carcinoma.
  • PURPOSE OF REVIEW: Chemoradiation represents the standard of care for most patients with localized squamous cell carcinoma of the anal canal.
  • This article reviews randomized trials and recent studies on chemoradiation for anal cancer.
  • Recent studies have started to evaluate intensity modulated radiation therapy for anal cancer, in an effort to reduce acute and long-term toxicity from radiotherapy.
  • SUMMARY: The role of cisplatin in anal cancer is not completely clear, although an ongoing randomized trial (Anal Cancer Trial II) may help clarify the role of cisplatin.
  • Studies on tumor biology and patient genetics are warranted to identify patients that are most likely to benefit from newer locoregional and systemic therapies.
  • Intensity modulated radiation therapy appears to be a promising approach for reducing treatment-related toxicity in anal cancer patients.
  • The Radiation Therapy Oncology Group (RTOG) is conducting a phase II trial evaluating the multi-institutional feasibility of intensity modulated radiation therapy for anal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Radiation-Sensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545807.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 21
  •  go-up   go-down


52. Hatfield P, Cooper R, Sebag-Montefiore D: Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):419-24
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma.
  • PURPOSE: To report the results of patients with early-stage anal cancer treated using a low-dose, reduced-volume, involved-field chemoradiotherapy protocol.
  • Of the 21 patients, 17 had had lesions that were excised with close (<1 mm) or involved margins, 1 had had microinvasive disease on biopsy, and 3 had had macroscopic tumor <2 cm in diameter (T1).
  • CONCLUSION: The results of our study have shown that for patients with anal carcinoma who have residual microscopic or very-small-volume disease, a policy of low-dose, reduced-volume, involved-field chemoradiotherapy produces excellent local control and disease-free survival, with low rates of acute and late toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Dose Fractionation. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919842.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


53. Crehange G, Bosset M, Lorchel F, Dumas JL, Buffet-Miny J, Puyraveau M, Mercier M, Bosset JF: Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum; 2007 Jan;50(1):43-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining cisplatin and mitomycin with radiotherapy in anal carcinoma.
  • PURPOSE: The European Organization for Research and Treatment of Cancer (EORTC) phase II study No. 22953 demonstrated the feasibility of reducing the overall treatment time of chemoradiation, delivering mitomycin C twice rather than once and fluorouracil during the whole treatment.
  • We tested the feasibility of chemoradiation in anal carcinoma with mitomycin and cisplatin in a phase II study.
  • METHODS: Twenty-one patients with locally advanced anal carcinoma (15 women, 6 men) were treated.
  • CONCLUSIONS: Combining radiation with mitomycin and cisplatin in patients with locally advanced anal cancer is feasible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma / drug therapy. Carcinoma / radiotherapy. Cisplatin / administration & dosage. Mitomycin / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy Dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089083.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


54. Wu M, Zhang SW, Han RQ, Zhou JY, Zou XN, Chen WQ: [Analysis on the mortality of colorectal and anal cancer in China during 2004 - 2005]. Zhonghua Yu Fang Yi Xue Za Zhi; 2010 May;44(5):403-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis on the mortality of colorectal and anal cancer in China during 2004 - 2005].
  • OBJECTIVE: To describe the mortality of colorectal and anal cancer in the Chinese population during 2004 - 2005.
  • METHODS: Mortality of colorectal and anal cancer from The 3rd National Death Retrospective Sampling Survey (2004 - 2005) were analyzed, with that the total population was 142 660 482 person-year and the number of death cases was 10 586.
  • Crude death rate, age-standardized death rate by Chinese standard population (CASR) and world standard population (WASR), the constitute proportion to all cancer deaths and rank of cancer death were calculated and compared with The 1st (during 1973 - 1975) and The 2nd (during 1990 - 1992) National Death Retrospective Surveys.
  • RESULTS: The mortality of colorectal and anal cancer in China was 7.42/100 000 (10 586/142 660 482) during 2004 - 2005, accounting for 5.46% of total cancer deaths and ranked the 5th leading cause of death from cancer.
  • Compared to the crude death rate 5.30/100 000 and CASR 4.54/100 000 during 1990 - 1992, the crude death rate and CASR from colorectal and anal cancer increased by 40.00% and 5.51%, whereas compared to the crude death rate 4.17/100 000 and CASR 4.27/100 000 during 1973 - 1975, the crude death rate and CASR had increased by 77.94% and 12.18% respectively.
  • CONCLUSION: The mortality of colorectal and anal cancer has been increasing rapidly in China.
  • [MeSH-major] Anus Neoplasms / mortality. Colorectal Neoplasms / mortality

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654228.001).
  • [ISSN] 0253-9624
  • [Journal-full-title] Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
  • [ISO-abbreviation] Zhonghua Yu Fang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


55. Christensen AF, Nielsen BM, Engelholm SA: Three-dimensional endoluminal ultrasound-guided interstitial brachytherapy in patients with anal cancer. Acta Radiol; 2008 Mar;49(2):132-7
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional endoluminal ultrasound-guided interstitial brachytherapy in patients with anal cancer.
  • BACKGROUND: New techniques using image guidance other than computed tomography (CT) and traditional two-dimensional (2D) endosonography might improve interstitial brachytherapy in patients with anal cancer.
  • MATERIAL AND METHODS: Seventeen patients with anal carcinoma were referred to interstitial brachytherapy under 3D endosonographic guidance after external radiotherapy.
  • The procedure was initiated by anal endosonography performed with a 10-MHz rotating endoprobe.
  • Cross-sectional images of the anal sphincters were stored on a 3D system during retraction of the endoprobe through the anal canal.
  • The needles were inserted through holes in an externally fixated anal template.
  • A repeated endosonography assured that optimal tumor coverage could be obtained by adjusting the number, dwell positions, and/or position of the needles.
  • CONCLUSION: 3D endosonography guidance of interstitial brachytherapy in anal carcinoma seems to optimize the implant procedure and offer better information for dose planning.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Brachytherapy / instrumentation. Brachytherapy / methods. Imaging, Three-Dimensional / methods. Ultrasonography, Interventional / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300134.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


56. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • RESULTS: The non-PET staging was Stage I(8), Stage II(18), Stage III(22), and Stage IV(2)s.
  • The primary was strongly FDG avid in 98% with non-excised tumors compared to CT (58%).
  • Post-treatment PETs at median 17 weeks (range 9-28) showed complete responses in 20 (80%) and 5 (20%) partial responses (PR).
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


57. Kreuter A, Brockmeyer NH, Wieland U: [Anal intraepithelial neoplasia and anal carcinoma: an increasing problem in HIV patients]. Hautarzt; 2010 Jan;61(1):21-6
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal intraepithelial neoplasia and anal carcinoma: an increasing problem in HIV patients].
  • [Transliterated title] Anale intraepitheliale Neoplasie und Analkarzinom : Ein zunehmendes Problem bei Menschen mit HIV-Infektion.
  • Anal dysplasia is common in HIV patients, especially in HIV-positive men having sex with men (MSM).
  • High-grade anal dysplasia can progress to invasive anal cancer.
  • As in cervical carcinoma, there is a cause and effect relationship between anal cancer and human papillomavirus (HPV) infection, especially with high-risk types such as HPV16.
  • Several experts have recommended screening programs for anal cancer, including anal cytology along the lines of the Pap smear in women.
  • Clinical inspection, lesion biopsy, and treatment of anal dysplasia are performed under high-resolution anoscopy.
  • Anal cancer is divided into cancer of the anal margin and cancer of the anal canal.
  • Early cancer of the anal margin is excised akin to squamous cell cancer of the exposed skin, whereas cancer of the anal canal is treated by radiochemotherapy.
  • Physicians working in the field of HIV/AIDS should regularly screen their patients for the presence of anal dysplasia and anal cancer.
  • Basic diagnostic workup includes clinical inspection of the perianal area, digital rectal examination, and anal cytology.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / prevention & control. Carcinoma in Situ / virology. HIV Infections / complications. Precancerous Conditions / diagnosis. Precancerous Conditions / prevention & control

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] J Am Acad Dermatol. 2005 Apr;52(4):603-8 [15793509.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Br J Cancer. 1997;75(5):722-8 [9043031.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Int J STD AIDS. 2008 Feb;19(2):118-20 [18334066.001]
  • [Cites] Br J Surg. 1994 Apr;81(4):500-8 [8205420.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 Nov;6(11):925-34 [18410393.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Curr Opin Infect Dis. 2009 Apr;22(2):109-14 [19276878.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Int J Colorectal Dis. 2002 Jul;17(4):203-15 [12073068.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):433-8 [19587592.001]
  • (PMID = 19967333.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, Villalon-Gomez JM, Williams MA, Cress RD: Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer; 2008 Nov 15;113(10 Suppl):2892-900
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the burden of human papillomavirus-associated anal cancers in the US.
  • BACKGROUND: Anal cancer is an uncommon malignancy in the US; up to 93% of anal cancers are associated with human papillomavirus.
  • METHODS: Cases diagnosed between 1998 and 2003 from 39 population-based cancer registries were analyzed.
  • The following anal cancer histologies were included in the analysis: squamous cell, adenocarcinoma, and small cell/neuroendocrine carcinomas.
  • RESULTS: From 1998 through 2003, the annual age-adjusted invasive anal cancer incidence rate was 1.5 per 100,000 persons.
  • Squamous cell carcinoma (SCC) was the most common histology overall, accounting for 18,105 of 21,395 (84.6%) cases of anal cancer.
  • Incidence rates of anal SCC increased 2.6% per year on average.
  • CONCLUSIONS: Rates of anal SCC varied by sex, race, and ethnicity.
  • Continued surveillance and additional research are needed to assess the potential impact of the HPV vaccine on the anal cancer burden in the US.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):311-20 [12556684.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Am J Epidemiol. 1992 Jul 1;136(1):54-8 [1329500.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Am J Epidemiol. 1994 Jul 1;140(1):12-9 [8017399.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Semin Cancer Biol. 1998 Aug;8(4):307-13 [9870037.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8 [17065979.001]
  • [Cites] Stat Methods Med Res. 2006 Dec;15(6):547-69 [17260923.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents [17630336.001]
  • [Cites] Sex Transm Infect. 2007 Jul;83(4):257-66 [17664359.001]
  • [Cites] Cancer Causes Control. 2007 Dec;18(10):1175-86 [17805982.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • (PMID = 18980293.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS104103; NLM/ PMC2729501
  •  go-up   go-down


59. Patel HS, Silver AR, Northover JM: Anal cancer in renal transplant patients. Int J Colorectal Dis; 2007 Jan;22(1):1-5
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer in renal transplant patients.
  • PURPOSE: A comprehensive literature review was performed to examine the prevalence of anal cancer, anal intraepithelial neoplasia (AIN) and anal human papillomavirus (HPV) infection in renal transplant recipients who are at risk of anal cancer due to iatrogenic immunosuppression.
  • METHODS: Pertinent articles were identified from searches performed on the National Center for Biotechnology Information database using the following keywords: anal cancer, AIN, screening, renal transplant (or kidney transplant), organ transplant recipients and post-transplant malignancies.
  • The prevalence of anal HPV infection in established transplant patients is 47%, and the prevalence of anal HPV infection in new transplant patients is 23%.
  • The relative risk for anal cancer in renal transplant patients is 10.
  • CONCLUSIONS: As compared to HIV-positive male patients who practise anal intercourse, renal transplant patients showed a modest rise in relative risk for anal cancer.
  • Screening programmes to detect AIN in HIV-positive patients who practise anal intercourse have been introduced on a preliminary basis in sexual health clinics in the US and may become standard practise in this population.
  • The case for screening in renal transplant patients is unclear and would merit further investigation, especially with reference to the prevalence of anal HPV infection in this population.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma in Situ / etiology. Graft Rejection / prevention & control. Immunosuppression / adverse effects. Immunosuppressive Agents / adverse effects. Kidney Failure, Chronic / surgery. Kidney Transplantation
  • [MeSH-minor] Anus Diseases / epidemiology. Anus Diseases / virology. Humans. Papillomavirus Infections / epidemiology. Papillomavirus Infections / etiology. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1994 Mar;81(3):365-7 [8173899.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand A. 1986 Sep;94(5):343-9 [3766143.001]
  • [Cites] Br J Dermatol. 2000 Sep;143(3):513-9 [10971322.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] Transpl Int. 2004 Aug;17(7):366-9 [15349721.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Arch Intern Med. 2004 Jul 12;164(13):1373-88 [15249346.001]
  • [Cites] Br J Surg. 1994 Apr;81(4):500-8 [8205420.001]
  • [Cites] Nephrol Dial Transplant. 2004 Apr;19(4):945-51 [15031354.001]
  • [Cites] Obstet Gynecol. 1984 Oct;64(4):451-8 [6483293.001]
  • [Cites] Transplant Proc. 1991 Feb;23(1 Pt 2):1101-3 [1899153.001]
  • [Cites] Dis Colon Rectum. 1989 Dec;32(12):1016-22 [2556252.001]
  • [Cites] J Clin Pathol. 1997 Aug;50(8):625-34 [9301544.001]
  • [Cites] J Clin Pathol. 1998 Oct;51(10):737-40 [10023335.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] J Am Soc Nephrol. 2004 Jun;15(6):1582-8 [15153569.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] Top HIV Med. 2003 Mar-Apr;11(2):45-9 [12717041.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):651-5 [10655362.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand A. 1986 Jan;94(1):63-9 [3962680.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Transplantation. 1985 Jan;39(1):23-5 [3880960.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • (PMID = 16133005.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 29
  •  go-up   go-down


60. Young SC, Solomon MJ, Hruby G, Frizelle FA: Review of 120 anal cancer patients. Colorectal Dis; 2009 Nov;11(9):909-14
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of 120 anal cancer patients.
  • OBJECTIVE: Chemoradiotherapy is the mainstay of treatment for the majority of patients with anal cancer, with abdominoperineal resection reserved for salvage.
  • The purpose of this study was to evaluate our results after radiotherapy with or without chemotherapy, and/or surgery in terms of overall survival and colostomy free survival in patients with anal cancer.
  • METHOD: A review of patients diagnosed with anal cancer between 1991 and 2004 was performed.
  • CONCLUSION: Chemoradiation is effective organ preserving treatment for anal cancer.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Colostomy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Papillomavirus Infections / pathology. Salvage Therapy. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2009 Nov;11(9):914-6 [19832863.001]
  • (PMID = 19175651.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Patel CB, Ramos-Valadez DI, Haas EM: Robotic-assisted laparoscopic abdominoperineal resection for anal cancer: feasibility and technical considerations. Int J Med Robot; 2010 Dec;6(4):399-404
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic-assisted laparoscopic abdominoperineal resection for anal cancer: feasibility and technical considerations.
  • BACKGROUND: Robotic-assisted laparoscopic surgery is an emerging technology that may prove advantageous for complex colorectal procedures involving the irradiated pelvis, such as abdominoperineal resection for recurrent anal cancer.
  • METHODS: Over a 6 month period, five abdominoperineal resections were performed using the da Vinci® robot for recurrent anal cancer in patients initially treated with definitive chemoradiation therapy.
  • CONCLUSION: Robotic-assisted laparoscopic surgery for anal cancer was found to be a safe and feasible procedure.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Laparoscopy / methods. Perineum / surgery. Robotics / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20827795.001).
  • [ISSN] 1478-596X
  • [Journal-full-title] The international journal of medical robotics + computer assisted surgery : MRCAS
  • [ISO-abbreviation] Int J Med Robot
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Anal cancer incidence rates increased in antiretroviral era. Rates increased for men and women. AIDS Alert; 2006 Mar;21(3):22-3
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer incidence rates increased in antiretroviral era. Rates increased for men and women.
  • Investigators compared United States surveillance data for cancer in the pre-HIV era, HIV era, and antiretroviral treatment era and found that squamous cell carcinoma of the anal canal incidence rates increased significantly in the latter era.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Anus Neoplasms / epidemiology. HIV Infections / drug therapy


63. Glynne-Jones R, Mawdsley S: Anal cancer: is neoadjuvant cisplatin chemotherapy or chemoradiotherapy friend or foe? Nat Clin Pract Oncol; 2008 Dec;5(12):692-3
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: is neoadjuvant cisplatin chemotherapy or chemoradiotherapy friend or foe?
  • This Practice Point commentary discusses the findings of the Intergroup RTOG 98-11 trial, which aimed to investigate both the potential role of cisplatin as neoadjuvant chemotherapy, and also its role concurrently in combination with radiotherapy, for anal-canal carcinoma.
  • Although chemoradiotherapy has had an important effect on the treatment of anal cancer, and allows preservation of anorectal function with survival rates similar to or better than those of surgical treatment, overall survival rates for advanced tumors are still in the region of 50-60% at 5 years.
  • A strong theoretical rationale for cisplatin-based treatment in anal cancer exists; several phase II trials have demonstrated a high response rate with reduced colostomy rates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852720.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM: Magnetic resonance imaging of anal cancer. Clin Radiol; 2005 Oct;60(10):1111-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of anal cancer.
  • AIM: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) appearances of primary and recurrent anal carcinoma, and to demonstrate the commonest patterns of local and distant disease spread.
  • METHODS: A retrospective review was performed of 27 cases of biopsy-proven anal carcinoma, where MRI was used for primary staging (9 patients) or suspected recurrence (18 patients).
  • The size, extent and signal characteristics of the anal tumour were documented.
  • Lymph node metastases were of similar signal intensity to the anal cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179172.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Crum-Cianflone NF, Hullsiek KH, Marconi VC, Ganesan A, Weintrob A, Barthel RV, Agan BK, Infectious Disease Clinical Research Program HIV Working Group: Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS; 2010 Feb 20;24(4):535-43
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancers among HIV-infected persons: HAART is not slowing rising incidence.
  • OBJECTIVE: To evaluate the incidence rates of anal cancer over the HIV epidemic and assess the impact of HAART use on anal cancer events.
  • METHODS: We evaluated the incidence of and factors associated with anal cancer using longitudinal data from the prospective U.S.
  • RESULTS: Among 4506 HIV-infected men with 37 806 person-years of follow-up, anal cancer rates (per 100 000 person-years) increased five-fold, from 11 in the pre-HAART to 55 in the HAART era (P = 0.02).
  • At cancer diagnosis (n = 19), median age was 42 years, median CD4 cell count was 432 cells/microl, 74% had a CD4 nadir cell count less than 200 cells/microl, 42% had a prior AIDS event, and 74% had received HAART.
  • From separate models, prior AIDS event (hazard ratio 3.88, P = 0.01) and lower CD4 nadir (hazard ratio 0.85 per 50 cell, P = 0.03) were associated with anal cancer, with a trend for a history of gonorrhea (hazard ratio 2.43, P = 0.07).
  • Duration of HAART use was not associated with a reduced risk of anal cancer (hazard ratio 0.94, P = 0.42).
  • CONCLUSION: Incidence rates of anal cancer have progressively increased during the HIV epidemic.
  • Persons with a longer duration of HIV infection have a substantially higher rate of anal cancer.
  • As HIV-infected persons are experiencing longer life expectancies and HAART does not appear protective of anal cancer, studies on preventive strategies are needed.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):256-62 [11242198.001]
  • [Cites] Cancer. 2009 Feb 1;115(3):524-30 [19127538.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S42-8 [10430218.001]
  • [Cites] Ann Intern Med. 1999 Oct 5;131(7):502-6 [10507958.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Am J Surg. 2005 Nov;190(5):732-5 [16226949.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):474-9 [18202423.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 May;5(2):78-85 [18510893.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Lancet. 2008 Jul 26;372(9635):293-9 [18657708.001]
  • [Cites] J Public Health (Oxf). 2008 Sep;30(3):293-304 [18559368.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2892-900 [18980293.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • (PMID = 19926961.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / HU0001-05-2-0011; United States / NIAID NIH HHS / AI / Y01 AI005072; United States / PHS HHS / / HU0001-05-2-0011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS203436; NLM/ PMC3132114
  • [Investigator] Banks S; Bavaro M; Chun H; Decker C; Eberly L; Eggleston C; Hairston H; Hawkes C; Johnson A; Landrum M; Lifson A; Merritt S; O'Connell R; Okulicz J; Peel S; Polis M; Powers J; Tramont E; Whitman T; Wortmann G; Zapor M
  •  go-up   go-down


66. Meyer J, Willett C, Czito B: Current and emerging treatment strategies for anal cancer. Curr Oncol Rep; 2010 May;12(3):168-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current and emerging treatment strategies for anal cancer.
  • Concurrent radiotherapy and chemotherapy (5-fluorouracil and mitomycin-C) is established as a sphincter-preserving treatment for squamous cell carcinoma of the anal canal.
  • However, there is room for improvement in rates of tumor control as well as a need to reduce treatment-induced toxicity.
  • This review discusses the evolution of therapy for anal cancer, from early clinical trials establishing the current standard to more recent studies evaluating cisplatin, capecitabine, oxaliplatin, and cetuximab.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] Dis Colon Rectum. 1977 Nov-Dec;20(8):677-8 [923397.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6555-60 [18006754.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):143-9 [19203845.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Eur J Cancer. 2009 Nov;45(16):2782-91 [19643599.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72 (1):119-26 [18472366.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):474-9 [18202423.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):701-8 [10690556.001]
  • [Cites] Oncol Rep. 2007 Oct;18(4):775-8 [17786335.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] Radiother Oncol. 2008 Mar;86(3):428-34 [18006097.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Dec;65(1):197-9 [19727729.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):27-33 [23154075.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30 [19117696.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • (PMID = 20425076.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 30
  •  go-up   go-down


67. Zucchini C, Concu M, Martini F, Morelli C, Salfi N, Carinci P, Tognon M, Caramelli E: FHIT oncosuppressor gene expression profile in human anal cancers. Int J Biol Markers; 2007 Jan-Mar;22(1):39-42
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FHIT oncosuppressor gene expression profile in human anal cancers.
  • The FHIT gene, a member of the histidine triad gene family, is a tumor suppressor gene exhibiting deletions in the majority of human cancers.
  • Little is known about the molecular mechanisms involved in malignant transformation of the lining cells of the anus.
  • In this study FHIT gene expression was investigated in this particular kind of human cancer.
  • FHIT expression was comparatively analyzed at the mRNA level, by RT-PCR, in squamous anal cancers, normal anal tissue and peripheral blood samples. cDNA analyses showed variability in FHIT transcripts, without apparent effects on the predicted amino acid sequence.
  • Our data indicate that the FHIT mRNA detected in anal cancers and in normal samples is heterogeneous.
  • Immunohistochemical data suggest that the Fhit protein is expressed only in a fraction of the tumor cells, while it is strongly expressed in the epithelial cells of glands of the normal anal mucosa.
  • The absence or poor expression of the Fhit protein in anal cancers suggests a role for this tumor suppressor gene product, as a risk factor, in the onset of this human cancer, as reported before for other human gastrointestinal tumors.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Anus Neoplasms / metabolism. Neoplasm Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393360.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


68. Czito BG, Pepek JM, Meyer JJ, Yoo S, Willett CG: Intensity-modulated radiation therapy for anal cancer. Oncology (Williston Park); 2009 Nov 15;23(12):1082-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy for anal cancer.
  • The contemporary treatment of anal cancer is combined-modality therapy with radiation therapy, fluorouracil, and mitomycin.
  • Tempering these positive results is the high rate of treatment-related morbidity associated with chemoradiation therapy for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2009 Nov 15;23(12):1092, 1094, 1096 [20017292.001]
  • [CommentIn] Oncology (Williston Park). 2009 Nov 15;23(12):1096, 1098 [20017293.001]
  • (PMID = 20017291.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 42
  •  go-up   go-down


69. Doniec JM, Schniewind B, Kovács G, Kahlke V, Loehnert M, Kremer B: Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy. Surg Endosc; 2006 Apr;20(4):673-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy.
  • BACKGROUND: The most appropriate therapy for anal cancer is external beam radiotherapy (EBRT) combined with chemotherapy (CTX).
  • We report on our experience of combined modality therapy of anal cancer and transrectal ultrasound (TRUS)-guided high-dose rate (HDR) afterloading therapy, referring to results of a study published in 1998 by the coauthors.
  • METHODS: From 1993 to 2001, 50 patients with anal cancer were treated.
  • RESULTS: In five patients (10%), tumor recurrence occurred or the tumor did not respond to therapy, and four (8%) developed distant lymph nodes or organ metastases.
  • CONCLUSIONS: TRUS-guided brachytherapy permits excellent local tumor control and results in minimal treatment-related morbidity.
  • Consequently, TRUS-guided brachytherapy may be a useful addition to current combined modality treatment regimens for anal cancer.
  • [MeSH-major] Anus Neoplasms / diagnostic imaging. Anus Neoplasms / radiotherapy. Brachytherapy. Endosonography
  • [MeSH-minor] Aged. Combined Modality Therapy. Digestive System Surgical Procedures / adverse effects. Fecal Incontinence / epidemiology. Fecal Incontinence / etiology. Female. Humans. Incidence. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / surgery. Retreatment. Salvage Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Cancer. 1983 Apr 1;51(7):1291-6 [6825051.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):575-81 [9486607.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1569-79 [8156483.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):59-66 [8365944.001]
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):763-6 [6499614.001]
  • [Cites] Cancer. 1983 May 15;51(10):1830-7 [6831349.001]
  • [Cites] Radiother Oncol. 1996 Nov;41(2):131-4 [9004355.001]
  • [Cites] Cancer. 1981 Jul 15;48(2):411-5 [7237411.001]
  • [Cites] Dis Colon Rectum. 1998 Feb;41(2):169-76 [9556240.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Cancer Radiother. 1999 Nov-Dec;3(6):461-7 [10630158.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):778-82 [7172946.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1226-33 [10189126.001]
  • [Cites] Dis Colon Rectum. 1991 Jun;34(6):482-6 [1903692.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):313-24 [9069302.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1736-40 [8448738.001]
  • (PMID = 16432657.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


70. Hoots BE, Palefsky JM, Pimenta JM, Smith JS: Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer; 2009 May 15;124(10):2375-83
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions.
  • A systematic review was conducted of HPV type distribution in anal cancer and anal high-grade and low-grade squamous intraepithelial lesions (HSIL and LSIL).
  • A total of 1,824 cases were included: 992 invasive anal cancers, 472 HSIL cases and 360 LSIL cases.
  • Crude HPV prevalence in anal cancer, HSIL, and LSIL was 71, 91 and 88%, respectively.
  • HPV16/18 prevalence was 72% in invasive anal cancer, 69% in HSIL and 27% in LSIL.
  • The HPV 16 and/or 18 prevalence in invasive anal cancer cases was similar to that reported in invasive cervical cancer.
  • If ongoing clinical trials show efficacy in preventing anal HPV infection and associated anal lesions, prophylactic HPV vaccines may play an important role for the primary prevention of these cancers in both genders.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Papillomaviridae / isolation & purification
  • [MeSH-minor] DNA, Viral / genetics. Female. Humans. Male. Neoplasm Invasiveness. Species Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19189402.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Number-of-references] 26
  •  go-up   go-down


71. Dunleavey R: The role of viruses and sexual transmission in anal cancer. Nurs Times; 2005 Mar 1-7;101(9):38-41
MedlinePlus Health Information. consumer health - Viral Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of viruses and sexual transmission in anal cancer.
  • Research has focused on the link between sexual activity, viral infection and cervical cancer.
  • However, a parallel situation can be seen with anal cancer.
  • Although less common than cervical cancer, anal cancer is a significant problem among certain groups.
  • In the male homosexual population it occurs in 35 out of every 100,000 men, a figure comparable with the rate of cervical cancer in women before cervical screening programmes were instigated (Klenke and Palefsky, 2003).
  • [MeSH-major] Anus Neoplasms / virology. Disease Transmission, Infectious. Homosexuality, Male. Virus Diseases / transmission
  • [MeSH-minor] Adult. Anal Canal / pathology. Causality. Female. Great Britain / epidemiology. HIV Infections / epidemiology. Humans. Incidence. Male. Mass Screening / methods. Papillomaviridae / pathogenicity. Papillomavirus Infections / epidemiology. Precancerous Conditions / diagnosis. Risk Factors. Sex Distribution. United States / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783159.001).
  • [ISSN] 0954-7762
  • [Journal-full-title] Nursing times
  • [ISO-abbreviation] Nurs Times
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 20
  •  go-up   go-down


72. Christensen AF, Nyhuus B, Nielsen MB: Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer. Dis Colon Rectum; 2009 Mar;52(3):484-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer.
  • PURPOSE: This study was designed to evaluate the interobserver and intraobserver agreement of two-dimensional (2-D) and three-dimensional (3-D) anal endosonography for the detection of local recurrence anal carcinoma.
  • METHODS: Thirty-six patients were treated for anal carcinoma, and seven had recurrent disease.
  • The observers scored each examination according to the following scale regarding presence of local recurrence: 1 = no finding/benign findings; 2 = properly benign findings; 3 = suspicious findings/malignant findings.
  • CONCLUSIONS: Three-dimensional endosonography proved to have significantly better interobserver and intraobserver agreement than 2-D endosonography concerning detection of recurrent anal cancer.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Endosonography. Neoplasm Recurrence, Local / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / ultrasonography. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Observer Variation. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333050.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Abramowitz L, Mathieu N, Roudot-Thoraval F, Lemarchand N, Bauer P, Hennequin C, Mitry E, Romelaer C, Aparicio T, Sobhani I: Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. Aliment Pharmacol Ther; 2009 Aug 15;30(4):414-21
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients.
  • BACKGROUND: Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.
  • AIM: To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV- patients in the highly active antiretroviral treatment (HAART) era.
  • METHODS: We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004.
  • No significant differences were observed in the tumour stage, pelvic radiotherapy dose or concomitant chemotherapy, according to the HIV status.
  • CONCLUSIONS: The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV- patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / drug therapy. HIV Seropositivity / complications


74. Blumetti J, Bastawrous AL: Epidermoid cancers of the anal canal: current treatment. Clin Colon Rectal Surg; 2009 May;22(2):77-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid cancers of the anal canal: current treatment.
  • Epidermoid carcinoma of the anal canal is an uncommon disease, but has increased in incidence with the HIV epidemic.
  • This review provides an overview of the historical, current, and future treatments of epidermoid anal canal malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2004 Nov 27;329(7477):1272-6 [15564260.001]
  • [Cites] ANZ J Surg. 2004 Jul;74(7):541-6 [15230786.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):478-83 [17103253.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3669-71 [18519948.001]
  • [Cites] Surg Oncol. 1994 Jun;3(3):135-46 [7952397.001]
  • [Cites] Eur J Surg Oncol. 2008 Aug;34(8):890-4 [18178364.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):506-12 [11330577.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):886-91 [11485523.001]
  • [Cites] Am J Surg. 1976 Mar;131(3):275-80 [1259098.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1305-9 [15484343.001]
  • [Cites] Br J Surg. 2005 May;92(5):605-14 [15739215.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1176-81 [15906137.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Colorectal Dis. 2006 Feb;8(2):124-9 [16412072.001]
  • [Cites] Am J Surg. 1991 Dec;162(6):580-4 [1670229.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):2-9 [18030528.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] Dis Colon Rectum. 2008 Feb;51(2):147-53 [18180997.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26 [18472366.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):43-8 [6691550.001]
  • [Cites] Cancer. 1983 May 15;51(10):1826-9 [6831348.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):709-11 [8348857.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Dis Colon Rectum. 1981 Mar-Apr;24(2):73-5 [7215078.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1259-73 [12873670.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102 [15629599.001]
  • (PMID = 20436831.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780240
  • [Keywords] NOTNLM ; Anal canal malignancy / Nigro protocol / chemoradiation / epidermoid carcinoma
  •  go-up   go-down


75. Monsonego J: [Anal cancer and human papillomaviruses: a perspective based on the cervical cancer model]. Gynecol Obstet Fertil; 2010 Apr;38(4):250-4
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer and human papillomaviruses: a perspective based on the cervical cancer model].
  • [Transliterated title] Cancer anal et papillomavirus humains: une pathologie en miroir de celle du cancer du col utérin.
  • Anal cancer is a rare pathology in the general population but the incidence of this cancer has been on the rise for certain high-risk groups, such as homosexual men and immunodepressed subjects.
  • The incidence of anal cancer is 10 times higher in the HIV-positive population than in the female population in general.
  • Moderate to severe dysplasias (AIN2-3) are types of precancerous lesions that usually precede the appearance of the cancer.
  • In anal cancer, HPV16 is present in over 75% of the cases.
  • The prevalence of HPV in anal cancer is higher in women (90%) than in men (75%).
  • Squamous cervical and anal cancers have strong similarities founded on the causal association to HPV, in particular HPV16.
  • Recent data indicate that anti-HPV vaccination has a significant potential in preventing HPV infections, precancerous lesions, and anal cancer in the general population as well as in the high-risk groups.
  • [MeSH-major] Anus Neoplasms / epidemiology. Anus Neoplasms / virology. Human papillomavirus 16. Human papillomavirus 18. Papillomavirus Infections / epidemiology. Precancerous Conditions / virology. Uterine Cervical Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20362481.001).
  • [ISSN] 1769-6682
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 24
  •  go-up   go-down


76. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H: Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis; 2006 Jul 15;43(2):223-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review.
  • Individuals with human immunodeficiency virus (HIV) infection are at increased risk for human papillomavirus-related squamous cell cancer of the anus.
  • Screening HIV-infected patients for squamous cell cancer of the anus and human papillomavirus-related anal dysplasia may prevent excess morbidity and mortality.
  • We have conducted a systematic review of the indirect evidence in the literature regarding the utility of anal Papanicolau (Pap) smear screening of HIV-infected individuals in the highly active antiretroviral therapy era.
  • Although there are no published studies evaluating the efficacy of anal Pap smear screening for preventing squamous cell cancer of the anus or anal intraepithelial neoplasia, we reviewed data regarding the burden of disease, anal Pap smear sensitivity and specificity, the prevalence of anal dysplasia, and 1 cost effectiveness study.
  • The available evidence demonstrates that HIV-infected individuals have an increased risk for squamous cell cancer of the anus and anal intraepithelial neoplasia.
  • This review identifies important areas for further study before routine anal Pap smear screening can be recommended.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. HIV Infections / complications. Papanicolaou Test. Papillomavirus Infections / diagnosis. Precancerous Conditions / diagnosis. Vaginal Smears
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Carcinoma in Situ / diagnosis. Carcinoma in Situ / etiology. Female. Humans. Male. Mass Screening. Papillomaviridae


77. Midtgaard J, Hansen MJ, Grandjean B: Modesty and recognition--a qualitative study of the lived experience of recovery from anal cancer. Support Care Cancer; 2009 Sep;17(9):1213-22
MedlinePlus Health Information. consumer health - Stress.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modesty and recognition--a qualitative study of the lived experience of recovery from anal cancer.
  • BACKGROUND: Anal cancer is a rare disease within the cancer spectrum.
  • AIM: The objective of this study was to describe the lived experiences of recovery from anal cancer, including which and how resources may help survivors of anal cancer to resist and to manage potentially complex stressors encountered in the recovery from the disease.
  • Sixteen individuals (11 women and five men; average age 52 years), who had completed therapy for anal cancer (average 31 months ago), participated in the study.
  • FINDINGS: The analysis revealed two concepts, modesty and recognition, which describe the essence of the lived experience of anal cancer, and which each appear to be important resistance resources.
  • DISCUSSION: Anal cancer appears to lack attention and deserved recognition from professional and social services, which in itself may lead to mistrust and devaluation of the individual seeking support.
  • [MeSH-major] Anus Neoplasms / psychology. Interpersonal Relations. Stress, Psychological. Survivors / psychology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Soc Sci Med. 1999 Apr;48(8):977-88 [10390038.001]
  • [Cites] Eur J Cancer Care (Engl). 2006 Jul;15(3):244-51 [16882120.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Sep;17 (6):469-77 [16149292.001]
  • [Cites] Health Promot Int. 2006 Sep;21(3):238-44 [16717056.001]
  • [Cites] Lancet. 2001 Aug 11;358(9280):483-8 [11513933.001]
  • [Cites] Fam Pract. 1993 Jun;10(2):201-6 [8359612.001]
  • [Cites] Am J Manag Care. 2002 Dec;8(18 Suppl):S550-9 [12512979.001]
  • [Cites] JAMA. 2000 Jul 19;284(3):357-62 [10891968.001]
  • [Cites] J Epidemiol Community Health. 2005 Jun;59(6):440-2 [15911636.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Dec;16(8):530-5 [15630846.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1588-94 [10408404.001]
  • [Cites] Eur J Cancer Care (Engl). 2007 Jan;16(1):17-25 [17227349.001]
  • [Cites] Med Health Care Philos. 2000;3(3):257-64 [11200026.001]
  • [Cites] Oncologist. 2007 May;12(5):524-34 [17522240.001]
  • [Cites] Gen Hosp Psychiatry. 2000 May-Jun;22(3):200-5 [10880715.001]
  • [Cites] Acta Oncol. 2008;47(1):47-55 [17926146.001]
  • (PMID = 19172304.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


78. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG: US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol; 2009 Mar 1;27(7):1116-21
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.
  • PURPOSE: The US Gastrointestinal Intergroup Radiation Therapy Oncology Group 98-11 anal carcinoma trial showed that cisplatin-based concurrent chemoradiotherapy resulted in a significantly higher rate of colostomy compared with mitomycin-based therapy.
  • Established prognostic variables for patients with anal carcinoma include tumor diameter, clinical nodal status, and sex, but pretreatment variables that would predict the likelihood of colostomy are unknown.
  • In the multivariate analysis, tumor-related prognosticators for poorer OS included node-positive cancer (P < or = .0001), large (> 5 cm) tumor diameter (P = .01), and male sex (P = .016).
  • In the pretreatment variables category, only large tumor diameter independently predicted for TTC (P = .008).
  • Similarly, the cumulative 5-year colostomy rate was statistically significantly higher for large tumor diameter than for small tumor diameter (Gray's test; P = .0074).
  • CONCLUSION: The combined analysis of the two arms of RTOG 98-11, representing the largest prospective database, reveals that tumor diameter (irrespective of the nodal status) is the only independent pretreatment variable that predicts TTC and 5-year colostomy rate in patients with anal carcinoma.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Cancer. 1983 May 15;51(10):1826-9 [6831348.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):67-73 [7690019.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102 [15629599.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3008-15 [15860857.001]
  • [Cites] Curr Opin Oncol. 2007 Jul;19(4):396-400 [17545807.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):383-90 [18501454.001]
  • [CommentIn] J Clin Oncol. 2009 Jun 20;27(18):3064; author reply 3065 [19414660.001]
  • (PMID = 19139424.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR025741; United States / NCI NIH HHS / CA / CA21661; United States / NCI NIH HHS / CA / U10 CA37422; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / U10CA32115; United States / NCI NIH HHS / CA / U10 CA032115
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2667813
  •  go-up   go-down


79. Karandikar SS, Borley A, Crosby T, Williams G, Reynolds S, Radcliffe AG: A five-year audit of anal cancer in Wales. Colorectal Dis; 2006 May;8(4):266-72
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A five-year audit of anal cancer in Wales.
  • OBJECTIVES: A retrospective audit has been undertaken of Squamous (epidermoid) type of anal cancer diagnosed and treated in the principality of Wales over a five-year period (1995-99) with follow-up until 2005.
  • METHODS: Patients were identified from the Welsh Cancer Registry and the pathology databases of the 17 acute hospitals in Wales.
  • Twenty-six anal cancers were diagnosed per year in the region.
  • CONCLUSIONS: This is a unique regional audit of anal cancer.
  • This study concurs that Human Papilloma Virus appears to predispose to Squamous anal cancer.
  • As recommended by NICE all patients should be referred to a multidisciplinary anal cancer team, which can provide individual treatment plans.
  • Increased specialization could mean specialist regional MDTs for anal cancer.
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Medical Audit. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Wales / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630228.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Ramamoorthy S, Luo L, Luo E, Carethers JM: Tobacco smoking and risk of recurrence for squamous cell cancer of the anus. Cancer Detect Prev; 2008;32(2):116-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tobacco smoking and risk of recurrence for squamous cell cancer of the anus.
  • OBJECTIVE: Squamous cell cancer of the anus is associated with multiple risk factors, including infection with human papillomavirus, immunosuppression, chronic inflammation, and tobacco smoking, although there is little data on these factors for the prediction of recurrent disease.
  • Here, we evaluated the risk of recurrence and mortality of anal carcinoma in association with tobacco smoking.
  • METHODS: We conducted a retrospective review of cases of anal carcinoma from two local hospitals.
  • We obtained information on treatment response and cancer recurrence, as well as tobacco usage from medical records.
  • RESULTS: We identified 64 patients with squamous cell cancer of the anus, and 34 of these (53%) had a tobacco smoking history.
  • Current smokers had higher carcinoma recurrence rates (11/34, 32%) than non-smokers (6/30, 20%).
  • Overall mortality was 33% (21/64), and cancer-related mortality was 23% (15/64).
  • Smokers were more likely to die from recurrence than non-smokers, with 45% of smokers dead compared to only 20% of non-smokers by 5 years after treatment.
  • CONCLUSION: Tobacco smoking appears to be associated with anal carcinoma disease recurrence, and is related to increased mortality.
  • This data suggests that patients should be cautioned about tobacco smoking once a diagnosis of anal carcinoma is made in attempt to improve their long-term outcome.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Dec 1;86(11):2337-45 [10590376.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1544-9 [12697879.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Anesth Analg. 1986 Nov;65(11):1186-8 [3767017.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):159-63 [8417381.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Am J Prev Med. 1995 Jul-Aug;11(4):245-50 [7495601.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2428-36 [16634096.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):853-8 [16815535.001]
  • [Cites] Clin Infect Dis. 2000 Sep;31(3):808-12 [11017836.001]
  • (PMID = 18639388.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067287; United States / NIDDK NIH HHS / DK / R24 DK080506; United States / NIDDK NIH HHS / DK / DK067287-01A2; United States / NIDDK NIH HHS / DK / R24 DK080506-01; United States / NIDDK NIH HHS / DK / R01 DK067287-01A2
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS209533; NLM/ PMC3427794
  •  go-up   go-down


81. D'Souza G, Cook RL, Ostrow D, Johnson-Hill LM, Wiley D, Silvestre T: Anal cancer screening behaviors and intentions in men who have sex with men. J Gen Intern Med; 2008 Sep;23(9):1452-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer screening behaviors and intentions in men who have sex with men.
  • BACKGROUND: The incidence of anal cancer has increased in the past decade, especially among men who have sex with men (MSM) and HIV-infected individuals.
  • There is controversy about whether to routinely screen for anal cancer in MSM.
  • OBJECTIVES: To determine whether current anal cancer screening behaviors, intention, and concern differ by HIV serostatus and to identify characteristics of men who intend to seek anal cancer screening.
  • MEASUREMENTS: Self-reported anal cancer screening history, attitudes, and intentions.
  • RESULTS: A history of anal warts was relatively common in these men (39%), whereas having a recent anal Pap test (5%), intention to seek anal cancer screening in the next 6 months (12%), and concern about anal cancer (8.5%) were less common.
  • Intention to seek anal cancer screening was associated with enabling factors (screening availability, health insurance), need factors (HIV-infection, history of anal warts), concern about anal cancer, and recent sexual risk taking.
  • Among four large US cities, there was significant regional variability in anal cancer screening behaviors, intention, and concern (all p<0.001).
  • Most MSM (76%) indicated they would go to their primary care physician for an anal health problem or question.
  • CONCLUSIONS: This study demonstrates a low rate of anal cancer screening and intention to screen among MSM.
  • As more evidence emerges regarding screening, primary care physicians should be prepared to discuss anal cancer screening with their patients.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Health Soc Behav. 1973 Dec;14(4):348-62 [4773924.001]
  • [Cites] AIDS Behav. 2008 Jan;12(1):127-38 [17410419.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Soc Sci Med. 1991;32(6):733-41 [2035050.001]
  • [Cites] MMWR CDC Surveill Summ. 1992 Apr 24;41(2):1-7 [1594012.001]
  • [Cites] Am J Epidemiol. 1995 Aug 1;142(3):323-30 [7631636.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):471-9 [8697393.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Health Psychol. 2000 May;19(3):283-9 [10868773.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):843-9 [11390533.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Fam Pract. 2003 Jun;20(3):294-303 [12738699.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):78-86 [14744737.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]
  • [Cites] Sex Health. 2004;1(3):137-40 [16335300.001]
  • [Cites] AIDS Patient Care STDS. 2006 Apr;20(4):293-303 [16623628.001]
  • [Cites] Patient Educ Couns. 2006 Nov;63(3):367-79 [16875796.001]
  • [Cites] Sex Transm Dis. 2007 Mar;34(3):170-3 [16837830.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • (PMID = 18618198.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NIAID NIH HHS / AI / U01-AI-35043; United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / U01-AI-35042; United States / NIAID NIH HHS / AI / U01-AI-37613; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NIAID NIH HHS / AI / U01-AI-35041; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / U01-AI-35040; United States / NIAID NIH HHS / AI / U01-AI-37984; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / U01-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI035039
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2518019
  •  go-up   go-down


82. Jiang Y, Mackley H, Cheng H, Ajani JA: Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy? J Natl Compr Canc Netw; 2010 Jan;8(1):135-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy?
  • Use of definitive chemoradiation as primary therapy for locoregional squamous cell carcinoma of the anal canal has been the standard approach in the United States since the 1980s.
  • Further improvement is likely depending on an increased understanding of the molecular biology of anal carcinoma and the addition of relevant biologic agents to chemoradiation to overcome chemoradiation resistance.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20064295.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Number-of-references] 38
  •  go-up   go-down


83. Jiménez W, Paszat L, Kupets R, Wilton A, Tinmouth J: Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol; 2009 Sep;114(3):395-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario.
  • OBJECTIVE: The oncogenic HPV subtypes responsible for gynecologic malignancies have also been implicated in the development of squamous cell cancer of the anus (SCAC).
  • SCAC is more common in women, typically presenting at an older age than gynecologic cancers.
  • The aim of this study was determine whether women diagnosed with anal cancer are more likely to have a history of HPV-related gynecological cancer as compared to a matched control group.
  • All women diagnosed with SCAC between 1992 and 2005, identified using ICD-9 codes (154.2, 154.3, 154.8) for anatomic site and ICD-O codes (8070-8075, 8120, 8123, 8124) for histologic subtype, were included as cases.
  • The exposure of interest was previous HPV-related gynecologic cancer, specifically cervical cancer, vulvar cancer and vaginal cancer.
  • Amongst the cases, there were 7 cervical, 3 vulvar and 1 vaginal cancers compared with 5 cervical, 0 vulvar and vaginal cancers in the 3264 controls.
  • Previous HPV-related gynecological cancer (cervical, vaginal or vulvar cancer) was significantly associated with SCAC (OR: 10.5, 95% C.I.: 3.6 to 30.3).
  • The median time between the diagnosis of anal cancer and previous cervical cancer was 20 years.
  • CONCLUSIONS: Previous HPV-related gynecological cancers are strongly associated with anal cancer and may occur decades before the anal cancer.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. Genital Neoplasms, Female / epidemiology. Neoplasms, Multiple Primary / epidemiology. Papillomavirus Infections / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19501390.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Ficari F, Fazi M, Garcea A, Nesi G, Tonelli F: Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula. Suppl Tumori; 2005 May-Jun;4(3):S31
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula.
  • This paper reports six patients with perianal Crohn's disease (CD), who developed anal cancer in chronic anal fistulas.
  • Tumors have been often diagnosed at an advanced stage and had a worse prognosis than cancers arising in the general population as tumor symptoms may mimic symptoms of CD, resulting in delay in diagnosis.
  • Patients with perianal CD should undergo a careful surveillance program for ano-rectal carcinoma, including routine biopsy of any suspected lesion.
  • [MeSH-major] Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / complications

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437885.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


85. Das P, Crane CH, Eng C, Ajani JA: Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res; 2008 Jan;2(1):10-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for squamous cell cancer of the anal canal.
  • Radiotherapy with concurrent chemotherapy is the standard of care for patients with nonmetastatic squamous cell anal cancer.
  • However, some heterogeneity exists among anal cancer patients in their outcomes.
  • This article reviews some of the clinical factors, treatment-related factors, and biologic factors that affect outcomes in patients with squamous cell anal cancer.
  • A better understanding of molecular biology is required to characterize the inherent heterogeneity of anal cancer and thereby develop optimal therapies.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):893-8 [15821121.001]
  • [Cites] Radiat Oncol. 2006;1:29 [16916475.001]
  • [Cites] Ann Surg Oncol. 2006 Aug;13(8):1047-53 [16865595.001]
  • [Cites] Acta Oncol. 2006;45(6):728-35 [16938816.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):206-11 [16904522.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):443-9 [16865241.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8688-96 [16246976.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1316-24 [16169674.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1347-55 [15719440.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1136-42 [15752894.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):309-14 [10487550.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] Radiother Oncol. 1999 May;51(2):153-60 [10435807.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1226-33 [10189126.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1333-6 [9579842.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):313-24 [9069302.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Ann Surg. 1994 Jul;220(1):40-9 [8024357.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):861-5 [8076484.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):67-73 [7690019.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Br J Radiol. 1989 Jan;62(733):53-8 [2492441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1141-51 [2599902.001]
  • [Cites] Br J Cancer. 1989 Jul;60(1):56-8 [2803916.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Dis Colon Rectum. 1986 May;29(5):336-40 [3698757.001]
  • [Cites] Radiother Oncol. 1985 Feb;3(2):145-50 [3920734.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):159-64 [3969957.001]
  • [Cites] Histopathology. 1990 Jun;16(6):545-55 [2376397.001]
  • [Cites] Cancer. 1981 Jul 15;48(2):411-5 [7237411.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1259-73 [12873670.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Pathology. 2002 Dec;34(6):573-8 [12555997.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1496-502 [11598480.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Histopathology. 2001 Jul;39(1):43-9 [11454043.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):107-12 [11319280.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] Virchows Arch. 2000 Mar;436(3):229-33 [10782881.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4330-7 [15781882.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1176-81 [15906137.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19259318.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2630809
  •  go-up   go-down


86. Christensen AF, Nielsen MB, Svendsen LB, Engelholm SA: Three-dimensional anal endosonography may improve detection of recurrent anal cancer. Dis Colon Rectum; 2006 Oct;49(10):1527-32
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional anal endosonography may improve detection of recurrent anal cancer.
  • PURPOSE: In our center since 2001, follow-up examination has included three-dimensional endosonography in all patients with suspicion of local recurrence of anal cancer.
  • METHODS: This prospective study included 38 consecutive patients who have had anal carcinoma and were investigated using three-dimensional endosonography in combination with anoscopy and digital rectal examination at Rigshospitalet from July 2001 to January 2005 under suspicion of local recurrence.
  • The observers scored each examination according to a five-point scale in which a score from 1 to 3 was regarded as benign endosonographic findings and a score from 4 to 5 was regarded as malignant endosonographic findings.
  • The endosonographic diagnosis for each examination was compared with histologic evaluation or when no biopsy had been taken with a follow-up period of at least six months.
  • CONCLUSIONS: This study indicates that three-dimensional endosonography surpasses two-dimensional endosonography in the evaluation of patients with suspicion of local recurrence of anal cancer especially in combination with anoscopy and digital rectal examination.
  • [MeSH-major] Anal Canal / ultrasonography. Anus Neoplasms / ultrasonography. Endosonography / methods. Imaging, Three-Dimensional. Neoplasm Recurrence, Local / ultrasonography

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988854.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Khanfir K, Ozsahin M, Bieri S, Cavuto C, Mirimanoff RO, Zouhair A: Patterns of failure and outcome in patients with carcinoma of the anal margin. Ann Surg Oncol; 2008 Apr;15(4):1092-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure and outcome in patients with carcinoma of the anal margin.
  • BACKGROUND: To evaluate the outcome of patients with carcinoma of anal margin in terms of recurrence, survival, and radiation toxicity.
  • METHODS: A series of 45 consecutive patients, with anal margin carcinoma treated between 1983 and 2006 with curative intent at two institutions, was retrospectively analyzed.
  • A surgical excision (close or positive surgical margin in 22 out of 29 patients) was realized before radiotherapy (RT).
  • The overall anal conservation rate was 80% for the whole series.
  • There was no significant association between local recurrence and patient age, histological grade, tumor size, T stage, overall treatment time, RT dose, or chemotherapy.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231838.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Ferenschild FT, Vermaas M, Hofer SO, Verhoef C, Eggermont AM, de Wilt JH: Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg; 2005 Nov;29(11):1452-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer.
  • The primary treatment for anal cancer is chemoradiation (CRT).
  • A major problem of surgery in the anal area is poor healing of the perineal wound.
  • Between 1985 and 2000, 129 patients treated for anal cancer were retrospectively reviewed.
  • Mean age at diagnosis was 59 (range: 41-83) years.
  • In the present study salvage APR in recurrent or persistent anal cancer results in good local control and 5-year overall survival of 30%.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Salvage Therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):574-7; discussion 577-8 [1587176.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1525-9 [9769399.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] J Gastrointest Surg. 2001 Jul-Aug;5(4):383-7 [11985979.001]
  • [Cites] Surg Gynecol Obstet. 1970 Nov;131(5):953-7 [5471546.001]
  • [Cites] Surg Clin North Am. 2002 Dec;82(6):1233-51 [12516851.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):525-9 [3942984.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):997-1005 [11240240.001]
  • [Cites] Br J Surg. 2003 May;90(5):575-80 [12734865.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1007-13 [11240241.001]
  • [Cites] Plast Reconstr Surg. 1988 Jan;81(1):62-73 [2962215.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Ann Surg Oncol. 1994 Mar;1(2):105-10 [7834434.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):405-9 [10430247.001]
  • [Cites] Clin Plast Surg. 1990 Oct;17(4):705-12 [2249391.001]
  • [Cites] AJR Am J Roentgenol. 1979 Nov;133(5):790-5 [115262.001]
  • [Cites] Dis Colon Rectum. 1989 Sep;32(9):773-7 [2503342.001]
  • [Cites] Proc R Soc Med. 1941 Jan;34(3):139-60 [19992316.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Arch Surg. 2000 Sep;135(9):1090-3; discussion 1094-5 [10982516.001]
  • [Cites] Surg Gynecol Obstet. 1985 Dec;161(6):509-17 [3934775.001]
  • [Cites] Br J Plast Surg. 1984 Jul;37(3):330-50 [6234962.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1425-9 [12390386.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1488-93 [9860327.001]
  • (PMID = 16222445.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Diamond C, Taylor TH, Aboumrad T, Bringman D, Anton-Culver H: Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis; 2005 May;32(5):314-20
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy.
  • OBJECTIVE: We sought to determine if the introduction of highly active antiretroviral therapy (HAART) corresponded with changes in anal squamous cell cancer rates among men with AIDS.
  • STUDY: We linked cancer registry data from 1988-2000 and AIDS registry data from 1981-July/2003 for San Diego County.
  • RESULTS: The annual incidence of invasive anal cancer increased from zero per 100,000 men with AIDS aged 25 to 64 years (95% confidence interval [CI], 0-226) in 1991 to 224 per 100,000 (95% CI, 102-425) in the year 2000.
  • Pre-HAART, the average annual incidence of invasive anal cancer was 49 per 100,000 men with AIDS aged 25 to 64 years (95% CI, 16-114) versus 144 per 100,000 (95% CI, 93-212) post-HAART.
  • The relative risk of invasive anal cancer among men with AIDS compared with men without known HIV/AIDS was 98 (95% CI, 36-264) pre-HAART and 352 (95% CI, 186-669) post-HAART.
  • The increased incidence of anal cancer among men with AIDS resulted in an increase in the overall rate of anal cancer among men in San Diego County.
  • CONCLUSIONS: The rising incidence of anal cancer among men with AIDS may be related to increased longevity with HAART and the consequent increased time at risk for the development of malignancy and/or the result of greater use of cytologic screening.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849533.001).
  • [ISSN] 0148-5717
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1K07CA096480-1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


90. Stelzer MK, Pitot HC, Liem A, Schweizer J, Mahoney C, Lambert PF: A mouse model for human anal cancer. Cancer Prev Res (Phila); 2010 Dec;3(12):1534-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mouse model for human anal cancer.
  • Human anal cancers are associated with high-risk human papillomaviruses (HPV) that cause other anogenital cancers and head and neck cancers.
  • As with other cancers, HPV16 is the most common high-risk HPV in anal cancers.
  • We describe the generation and characterization of a mouse model for human anal cancer.
  • This model makes use of K14E6 and K14E7 transgenic mice in which the HPV16 E6 and E7 genes are directed in their expression to stratified squamous epithelia.
  • HPV16 E6 and E7 possess oncogenic properties including, but not limited to, their capacity to inactivate the cellular tumor suppressors p53 and pRb, respectively.
  • Both E6 and E7 were found to be functionally expressed in the anal epithelia of K14E6/K14E7 transgenic mice.
  • To assess the susceptibility of these mice to anal cancer, mice were treated topically with dimethylbenz[a]anthracene (DMBA), a chemical carcinogen that is known to induce squamous cell carcinomas in other sites.
  • Histopathologic analyses confirmed that the HPV16 transgenic mice were increased in their susceptibility to anal cancers and precancerous lesions.
  • Biomarker analyses demonstrated that these mouse anal cancers exhibit properties that are similar to those observed in HPV-positive precursors to human anal cancer.
  • This is the first mouse model for investigating the contributions of viral and cellular factors in anal carcinogenesis, and should provide a platform for assessing new therapeutic modalities for treating and/or preventing this type of cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9094-103 [14645521.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4862-71 [12941807.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Cancer Res. 1982 Sep;42(9):3519-25 [6286109.001]
  • [Cites] J Pathol. 1990 Jun;161(2):99-103 [2199641.001]
  • [Cites] J Virol. 1996 Mar;70(3):1873-81 [8627712.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Nature. 1998 Nov 5;396(6706):84-8 [9817205.001]
  • [Cites] J Virol. 1999 Jul;73(7):5887-93 [10364340.001]
  • [Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14152-7 [16959885.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1626-35 [17308103.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4605-19 [17510386.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6106-12 [17616666.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):313-27 [17936557.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2668-73 [17721920.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11585-93 [18089787.001]
  • [Cites] Mol Cancer. 2008;7:3 [18184435.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Mod Pathol. 2010 Jan;23(1):144-50 [19838162.001]
  • [Cites] J Am Acad Dermatol. 2010 Sep;63(3):490-8 [20006407.001]
  • [Cites] Br J Dermatol. 2010 Jun;162(6):1269-77 [20184584.001]
  • [Cites] Virology. 2000 Feb 15;267(2):141-50 [10662610.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8173-80 [14678972.001]
  • (PMID = 20947489.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098428-08; United States / NCI NIH HHS / CA / P01 CA022443-330006; United States / NCI NIH HHS / CA / R01 CA098428-09; United States / NCI NIH HHS / CA / U01 CA141583; United States / NCI NIH HHS / CA / P01 CA022443-320006; United States / NCI NIH HHS / CA / CA098428-08; United States / NCI NIH HHS / CA / CA022443-330006; United States / NCI NIH HHS / CA / CA141583-02; United States / NCI NIH HHS / CA / U01 CA141583-01; United States / NIDCR NIH HHS / DE / R01 DE017315-04; United States / NCI NIH HHS / CA / CA141583-01; United States / NCI NIH HHS / CA / CA022443-320006; United States / NIDCR NIH HHS / DE / R01 DE017315; United States / NIDCR NIH HHS / DE / R01 DE017315-05; United States / NCI NIH HHS / CA / CI T32 CA090217; United States / NCI NIH HHS / CA / T32 CA090217; United States / NCI NIH HHS / CA / U01 CA141583-02; United States / NCI NIH HHS / CA / P01 CA022443; United States / NCI NIH HHS / CA / R01 CA098428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Repressor Proteins; 0 / oncogene protein E7, Human papillomavirus type 16; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ NIHMS211621; NLM/ PMC3006089
  •  go-up   go-down


91. Hogg ME, Popowich DA, Wang EC, Kiel KD, Stryker SJ, Halverson AL: HIV and anal cancer outcomes: a single institution's experience. Dis Colon Rectum; 2009 May;52(5):891-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV and anal cancer outcomes: a single institution's experience.
  • PURPOSE: The purpose of this study is to identify the effect of HIV status on outcome of treatment for squamous-cell carcinoma of the anal canal.
  • METHODS: A retrospective review was performed on all patients with squamous-cell carcinoma of the anal canal treated at a single academic institution between January 1996 and December 2006.
  • RESULTS: Our search identified 87 (21 HIV-positive) patients who had invasive squamous-cell cancer.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality. HIV Infections / mortality
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Capecitabine. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Colostomy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Mitomycin / therapeutic use. Mitoxantrone / therapeutic use. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Retrospective Studies


92. Mistrangelo M, Bellò M, Mobiglia A, Beltramo G, Cassoni P, Milanesi E, Cornaglia S, Pelosi E, Giunta F, Sandrucci S, Mussa A: Feasibility of the sentinel node biopsy in anal cancer. Q J Nucl Med Mol Imaging; 2009 Feb;53(1):3-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of the sentinel node biopsy in anal cancer.
  • AIM: Anal cancer is a rare neoplasm.
  • According to a European Organization for Research and Treatment of Cancer multivariate analysis, synchronous inguinal lymph node metastasis occurs in 10-25% of patients and constitutes an independent prognostic factor for local failure and overall mortality.
  • METHODS: Inguinal lymph node status was assessed using the sentinel node technique in 35 patients with anal cancer.
  • RESULTS: Histology revealed 23 squamous carcinomas, 10 basaloid carcinomas, 1 squamous carcinoma with basaloid areas and 1 spinocellular epithelioma associated with areas of Bowen's disease.
  • CONCLUSIONS: Given the correlation between prognosis and node involvement, sentinel node biopsy can be considered a simple method for adequate pretreatment staging of anal carcinoma.
  • [MeSH-major] Anus Neoplasms / diagnosis. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Inguinal Canal / pathology. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Staging. Recurrence

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337684.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


93. Fraunholz I, Rabeneck D, Weiss C, Rödel C: Combined-modality treatment for anal cancer: current strategies and future directions. Strahlenther Onkol; 2010 Jul;186(7):361-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined-modality treatment for anal cancer: current strategies and future directions.
  • BACKGROUND: Concurrent chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and mitomycin C (MMC) is the treatment of choice for anal carcinoma.
  • CONCLUSION: Concurrent 5-FU/MMC-CRT without induction or maintenance chemotherapy remains the standard of care for anal cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2008 Nov;184(11):592-7 [19016018.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Strahlenther Onkol. 2009 Jan;185(1):8-18 [19224142.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Eur J Cancer. 2009 Nov;45(16):2782-91 [19643599.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1731-6 [8625041.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Br J Cancer. 2010 Mar 30;102(7):1123-8 [20354531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72 (1):119-26 [18472366.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):20-3 [15923158.001]
  • [Cites] Oncology. 2009;77(5):293-9 [19923868.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):59-66 [8365944.001]
  • [Cites] Strahlenther Onkol. 2009 Jun;185(6):371-8 [19506820.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]
  • [Cites] Dis Colon Rectum. 2007 Mar;50(3):395-8 [17252287.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] Dis Colon Rectum. 2007 Jan;50(1):43-9 [17089083.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3229-34 [18490648.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Dec;65(1):197-9 [19727729.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Radiother Oncol. 1993 Jun;27(3):209-15 [8210457.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):942-9 [16648870.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • (PMID = 20582392.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 31
  •  go-up   go-down


94. Charnley N, Choudhury A, Chesser P, Cooper RA, Sebag-Montefiore D: Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. Br J Cancer; 2005 Apr 11;92(7):1221-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy.
  • Chemoradiotherapy (CRT) is accepted as the standard initial treatment for squamous cell anal cancer.
  • In all, 16 patients with biopsy-proven squamous cell carcinoma of the anal canal or margin and performance status or co-morbidity precluding the use of full-dose CRT were included in this protocol.
  • Patients received a dose of 30 Gy to the gross tumour volume plus 3 cm margin in all directions.
  • This is a well-tolerated regimen for elderly/poor performance patients with anal cancer, which can achieve high rates of local control and survival.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Fluorouracil / therapeutic use. Frail Elderly

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):65-9 [12118566.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1387-92 [9338461.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):2978-81 [15210736.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Dis Colon Rectum. 1977 Nov-Dec;20(8):677-8 [923397.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):778-82 [7172946.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] Radiother Oncol. 1985 Feb;3(2):145-50 [3920734.001]
  • [Cites] Dis Colon Rectum. 1987 May;30(5):324-33 [3568920.001]
  • [Cites] Dis Colon Rectum. 1987 Jul;30(7):495-502 [3109860.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1736-40 [8448738.001]
  • [Cites] Radiology. 1994 May;191(2):569-72 [8153343.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1352-7 [12778060.001]
  • (PMID = 15798772.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361984
  •  go-up   go-down


95. Jeffreys M, Rachet B, McDowell S, Habib AG, Lepage C, Coleman MP: Survival from rectal and anal cancers in England and Wales, 1986-2001. Eur J Cancer; 2006 Jul;42(10):1434-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival from rectal and anal cancers in England and Wales, 1986-2001.
  • The aim of this study was to investigate the effects of tumour and patient characteristics on trends in the survival of patients with cancer of the anus or rectum in England and Wales.
  • Relative survival up to 5 years after diagnosis was estimated, using deprivation-specific life tables.
  • Generalised linear models were used to estimate relative excess risks of death, adjusted for patient and tumour characteristics.
  • The results showed that 5-year relative survival was higher in women, younger patients and more affluent patients, and higher for anal cancer than rectal cancer.
  • This trend was not explained by changes in the distribution of age, anatomical site, morphology or deprivation.
  • The trend was more marked in younger and more affluent patients, and for adenocarcinoma and epidermoid carcinoma than for tumours with other morphology.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anus Neoplasms / mortality. England / epidemiology. Female. Humans. Middle Aged. Survival Analysis. Wales / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600590.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


96. Winton Ed, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, Leong T, Fay M, MacKay J, Drummond E, Ngan SY: The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer; 2009 Mar 10;100(5):693-700
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
  • Accurate inguinal and pelvic nodal staging in anal cancer is important for the prognosis and planning of radiation fields.
  • There is evidence for the role of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging and management of cancer, with early reports of an increasing role in outcome prognostication in a number of tumours.
  • We aimed to determine the effect of FDG-PET on the nodal staging, radiotherapy planning and prognostication of patients with primary anal cancer.
  • Sixty-one consecutive patients with anal cancer who were referred to a tertiary centre between August 1997 and November 2005 were staged with conventional imaging (CIm) (including computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound and chest X-ray) and by FDG-PET.
  • The tumour-stage group was changed in 23% (14 out of 61) as a result of FDG-PET (15% up-staged, 8% down-staged).
  • FDG-PET shows increased sensitivity over CIm for staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Mar;218(3):776-82 [11230656.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):168-71 [2703175.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):886-95 [11550162.001]
  • [Cites] Radiology. 1999 Nov;213(2):530-6 [10551237.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):272-8 [11703321.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):506-15 [11914889.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):179-84 [11925141.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):43-9 [12837154.001]
  • [Cites] Semin Surg Oncol. 2003;21(3):149-55 [14508847.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):451-8 [14978612.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] AJR Am J Roentgenol. 1983 Jan;140(1):95-9 [6600330.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1285-93 [6692319.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer. 1998 May 1;82(9):1664-71 [9576286.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1257-63 [10450675.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1301-15 [15793642.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):247-52 [16289647.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):254-61 [16545881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8 [16550384.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):419-24 [17919842.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • (PMID = 19259091.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2653751
  •  go-up   go-down


97. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Mary-Krause M, FHDH-ANRS CO 4: Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS; 2008 Jun 19;22(10):1203-11
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy.
  • OBJECTIVE: To describe the cases of anal cancer that appeared in the French Hospital Database on HIV between 1992 and 2004 and to study risk factors of anal cancer.
  • METHODS: We examined the incidence rates of anal cancer between 1992 and 2004 and the risk associated among 86,322 HIV-infected patients included in the French Hospital Database on HIV.
  • RESULTS: We identified 132 cases of anal cancer, including 124 cases in men (94%), of whom 75% had sex with men.
  • Median age at diagnosis was 42.8 years (interquartile range: 36.9-49.4).
  • At diagnosis, 103 patients (78%) were receiving combination antiretroviral therapy for a median of 37.1 months (interquartile range: 4.5-59.8).
  • Median survival after anal cancer diagnosis was 5 years.
  • The respective overall incidence rates of anal cancer per 100,000 person-years between 1992 and March 1996, April 1996 to 1998 and between 1999 and 2004 were 11 (95% confidence interval, 4-17), 18 (95% confidence interval, 10-27) and 40 (95% confidence interval, 32-47).
  • The risk of anal cancer was higher among men who have sex with men.
  • After adjustment for age at inclusion in the study, as well as gender, the HIV transmission group, the nadir CD4 cell count and AIDS status, the incidence was higher in the years 1999-2004 than in between 1992 to March 1996 (hazard ratio, 2.5; 95% confidence interval, 1.2-5.3), with no change in the years 1999-2004.
  • CONCLUSION: The incidence of anal cancer has increased among HIV-infected patients in France since 1996.
  • Although an ascertainment bias cannot be excluded, data indicate that combination antiretroviral therapy does not prevent anal cancer in these patients.
  • This supports the urgent need for developing anal cancer screening programs for HIV-infected men who have sex with men.
  • [MeSH-major] Anus Neoplasms / mortality. HIV Infections / mortality. Homosexuality, Male / statistics & numerical data

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525266.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Investigator] Abgrall S; Barin F; Bentata M; Billaud E; Boué F; Burty C; Cabié A; Costagliola D; Cotte L; De Truchis P; Duval X; Duvivier C; Enel P; Fredouille-Heripret L; Gasnault J; Gaud C; Gilquin J; Grabar S; Khuong MA; Lang JM; Lascaux AS; Launay O; Mahamat A; Mary-Krause M; Matheron S; Meynard JL; Pavie J; Pialoux G; Pilorgé F; Poizot-Martin I; Pradier C; Reynes J; Rouveix E; Simon A; Tattevin P; Tissot-Dupont H; Viard JP; Viget N; Aronica E; Pariente-Khayat A; Jacquemet N; Rivet A; Abgrall S; Costagliola D; Grabar S; Guiguet M; Lanoy E; Selinger-Leneman H; Liévre L; Mary-Krause M; Potard V; Bouvet E; Crickx B; Ecobichon JL; Leport C; Matheron S; Picard-Dahan C; Yeni P; Tisne-Dessus D; Weiss L; Salmon D; Sicard D; Auperin I; Gilquin J; Roudiére L; Viard JP; Boué F; Fior R; Delfraissy JF; Goujard C; Jung C; Lesprit PH; Desplanque N; Meynard JL; Meyohas MC; Picard O; Cadranel J; Mayaud C; Pialoux G; Bricaire F; Herson S; Katlama C; Simon A; Clauvel JP; Decazes JM; Gerard L; Molina JM; Diemer M; Sellier P; Berthé H; Dupont C; Chandemerle C; Mortier E; de Truchis P; Bentata M; Honoré P; Jeantils V; Tassi S; Mechali D; Taverne B; Gourdon F; Laurichesse H; Fresard A; Lucht F; Eglinger P; Faller JP; Bazin C; Verdon R; Boibieux A; Peyramond D; Livrozet JM; Touraine JL; Cotte L; Trepo C; Ravaux I; Tissot-Dupont H; Delmont JP; Moreau J; Gastaut JA; Poizot-Martin I; Retornaz F; Soubeyrand J; Allegre T; Blanc TA; Galinier A; Ruiz JM; Lepeu G; Granet-Brunello P; Esterni JP; Pelissier L; Cohen-Valensi R; Nezri M; Chadapaud S; Laffeuillade A; Reynes J; May T; Rabaud C; Billaud E; Raffi F; Pugliese P; Pradier C; Arvieux C; Michelet C; Borsa-Lebas F; Caron F; Fraisse P; Lang JM; Rey D; Arlet-Suau E; Cuzin L; Massip P; Thiercelin Legrand MF; Gustave Dron CF; Yasdanpanah Y; Pradinaud R; Sobesky M; Gaud C; Contant M
  •  go-up   go-down


98. Caricato M, Ausania F, Marangi GF, Cipollone I, Flammia G, Persichetti P, Trodella L, Coppola R: Surgical treatment of locally advanced anal cancer after male-to-female sex reassignment surgery. World J Gastroenterol; 2009 Jun 21;15(23):2918-9
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of locally advanced anal cancer after male-to-female sex reassignment surgery.
  • We present a case of a transsexual patient who underwent a partial pelvectomy and genital reconstruction for anal cancer after chemoradiation.
  • This is the first case in literature reporting on the occurrence of anal cancer after male-to-female sex reassignment surgery.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Reconstructive Surgical Procedures. Transsexualism / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Plast Surg. 2007 Aug;59(2):168-72 [17667411.001]
  • [Cites] Plast Reconstr Surg. 1980 Sep;66(3):401-6 [6999512.001]
  • (PMID = 19533817.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2699013
  •  go-up   go-down


99. Hirche C, Dresel S, Krempien R, Hünerbein M: Sentinel node biopsy by indocyanine green retention fluorescence detection for inguinal lymph node staging of anal cancer: preliminary experience. Ann Surg Oncol; 2010 Sep;17(9):2357-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy by indocyanine green retention fluorescence detection for inguinal lymph node staging of anal cancer: preliminary experience.
  • BACKGROUND: There is some evidence that sentinel lymph node (SLN) biopsy guided by dye injection and/or radioisotopes can improve staging of inguinal lymph nodes (LNs) in anal cancer.
  • This study was performed to investigate the feasibility of fluorescence detection of SLN and lymphatic mapping in anal cancer.
  • METHODS: Twelve patients with anal cancer without evidence for inguinal LN involvement were included in the study.
  • CONCLUSIONS: ICG fluorescence imaging allows intraoperative lymphatic mapping and transcutaneous SLN detection for selective biopsy of inguinal SLN in anal cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Indocyanine Green. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2011 Mar;18(3):901; author reply 902 [20717732.001]
  • (PMID = 20217256.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


100. Hatzaras I, Abir F, Kozol R, Sullivan P, Longo WE: The demographics, histopathology and patterns of treatment of anal cancer in Connecticut: 1980-2000. Conn Med; 2005 May;69(5):261-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The demographics, histopathology and patterns of treatment of anal cancer in Connecticut: 1980-2000.
  • OBJECTIVES: Examine the epidemiology and clinical characteristics of anal cancer in the State of Connecticut.
  • MATERIALS AND METHODS: The Department of Health Connecticut Tumor Registry resources were utilized for the years 1980-2000.
  • RESULTS: A total of 646 anal cancers (410 females, 236 males) were diagnosed (mean age: 63.4 years).
  • The most prominent histological type was squamous cell carcinoma, followed by adenocarcinoma and cloacogenic carcinoma.
  • CONCLUSIONS: Anal cancer incidence in Connecticut increased in the 21-year period 1980 to 2000, affecting the rate for African-American men more than other race-specific and gender-specific population subgroups.
  • Anal cancer affects women more often than men.
  • Squamous cell carcinoma is the most common histological type.
  • [MeSH-major] Adenocarcinoma / epidemiology. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colectomy / methods. Combined Modality Therapy. Connecticut / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16114640.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement